An ingestible stackable gastric resident system for gastrointestinal applications

Abstract

Some aspects are related to articles for delivering therapeutic agents to a location internal to a subject. In some embodiments, the articles may include a reservoir configured to contain a therapeutic agent, a magnetic component, and a tether linking the reservoir and the magnetic component. In some embodiments, a plurality of the articles may be ingested by a subject, and the magnetic component of the articles may self- assemble into a drug delivery system at a location internal of the subject. The reservoirs of the articles may contain a large amount of a therapeutic agent (e.g., up to 50 grams of therapeutic agent) in the system, in some embodiments, and the system may be configured to release the therapeutic agent over a long time (e.g., up at 365 days). Still other aspects are related to methods of administering and / or using the articles and systems, kits containing the same, or the like.

Description

[0001]AN INGESTIBLE STACKABLE GASTRIC RESIDENT SYSTEM FOR GASTROINTESTINAL APPLICATIONS RELATED APPLICATIONS This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 63 / 602,249, filed November 22, 2023, and entitled “AN INGESTIBLE STACKABLE GASTRIC RESIDENT SYSTEM FOR GASTROINTESTINAL APPLICATIONS,” which is incorporated herein by reference in its entirety for all purposes. TECHNICAL FIELD Ingestible articles for delivering therapeutic agents to and / or monitoring conditions of a subject, as well as related systems and methods, are generally described. BACKGROUND Patients are often instructed to follow a regimen regarding a therapeutic agent when receiving treatment, often times requiring the patient to adhere to the prescribed schedule over a long time. For example, a patient may take a tablet (e.g., a pill) containing the therapeutic agent once a day for 30 or more days to treat tuberculosis or other diseases. Such regimens for patients, however, may be difficult to adhere to over such long time due to varying schedules, socioeconomic statuses, and / or the quality of the medical team providing treatment, and failure to adhere to such a regimen may be detrimental to patient outcomes. Accordingly, improved systems and methods for long term delivery of therapeutic agents are needed. SUMMARY Ingestible articles for delivering therapeutic agents to a subject, as well as related systems and methods, are generally described. The subject matter of the present disclosure involves, in some cases, interrelated products, alternative solutions to a particular problem, and / or a plurality of different uses of one or more systems and / or articles. Some aspects are generally related to articles. In some embodiments, the article is for delivering a therapeutic agent to a location internal to a subject. In some embodiments, the article comprises a reservoir configured to receive a therapeutic agent, a magnetic component, and a tether operably linking the reservoir and the magnetic component, wherein the article is sized and adapted for ingestion such that the article resides at the location internal to the subject. In some embodiments, the reservoir of the article is a first reservoir and the tether is a first tether, the article further comprising at least a second reservoir and at least a second tether operably linking the second reservoir to the magnetic component. In some embodiments, the article further comprises a degradable linker operably linking the tether to the reservoir. In some embodiments, wherein, in the presence of a second article comprising a second magnetic component, the article and the second article become operably linked via the magnetic component and the second magnetic component. In some embodiments, the article further comprises a resistor associated with the magnetic component. In some embodiments, the second article further comprises a second reservoir operably linked to the second magnetic component by a second tether. In some embodiments, the reservoir of the article comprises at least one micro-outlet having a maximum cross-sectional dimension of less than or equal to 1 millimeter. In some embodiments, the reservoir of the article is configured to release a therapeutic agent at a rate of greater than or equal to 0.0001 g / day and less than or equal to 2 g / day through the micro-outlet. In some embodiments, the tether of the article comprises a suture, a metal, an inorganic material, and / or a polymer. In some embodiments, the tether of the article is degradable. In some embodiments, the article comprises a first configuration within a container and, after being ingested by a subject, the article is configured to be released from the container to comprise a second configuration at a location internal to the subject. In some embodiments, the reservoir of the article comprises an actuation mechanism. In some such embodiments, the actuation mechanism comprises a spring, an osmotic agent, and / or a swelling agent and is configured to disassemble the system. In some embodiments, the article further comprises the therapeutic agent in the reservoir. In some embodiments, the therapeutic agent of the article is a biological macromolecule, a small molecule, a vitamin, or a supplement. In some embodiments, the therapeutic agent of the article is a selective serotonin reuptake inhibitor, a blood thinning agent, a steroid, an antagonist, a cardiacalycoside, an alpha blocker, a cholesterol absorption inhibitor, a metabolite, an antihistamine, an opioid, a proton-pump inhibitor, an antibiotic, an anti-malarial agent, sulfonamides, a contraceptive, a stimulant, an analgesic, an anti-analgesic, an anti-inflammatory drug, nonsteroidal anti- inflammatory drug, an antipyretic, an immunosuppressant, a neuroprotective agent, an antipsychotic, a statin, an antidepressant, an antiepileptic, an anti-proliferative, an anti- cancer agent, an antimigraine drug, an antimicrobial, an antifungal, an antiviral agent, an antiretroviral agent, an aolytic, a bacteriostatic, a sedative, a hypnotic, a bronchodilator, an anti-asthma drug, a cardiovascular drug, anesthetic, an anticoagulant, a dopaminergic, an electrolyte, a gastro-intestinal drug, a muscle relaxant, a parasympathomimetic, an anorectic, an anti-narcoleptic, a protein, a peptide, a hormone, a nucleic acid, a gene construct, 3-hy-droxy-3-methyl-glutaryl (HMG) co-A reductase inhibitor, a mineral, 4 prostaglandin, a nutritional supplement, a corticosteroid, a nutraceutical, a plant extract, or a phytohormone. In some embodiments, the therapeutic agent of the article is a selective serotonin reuptake inhibitor, an antidepressant, an anxiolytic, a sedative, a hypnotic, an opioid, an antimigraine drug, a cholesterol absorption inhibitor, a substance abuse treatment, an immunosuppressant, an HMG co-A reductase inhibitor, a blood thinning agent, a cardiac glycoside, an antibiotic, a contraceptive, an analgesic, an anesthetic, a nonsteroidal anti-inflammatory drug, an antiepileptic, or an alpha blocker. In some embodiments, the article comprises a capsule defining an interior volume, a power source and / or an electronic component at least partially disposed within the interior volume of the capsule, a magnetic component and a tether operably linking the capsule and the magnetic component, wherein the article is sized and adapted for ingestion such that the article resides at the location internal to the subject. Some aspects are generally related to system. In some embodiments, the system is a self-assembling drug delivery system. In some embodiments, the system comprises a plurality of articles as described elsewhere herein, wherein each magnetic component of each article is configured to self-assemble at the location internal to the subject. In some embodiments, the system, when assembled, is sized and adapted to prevent passage of the system through a pylorus of the subject. In some embodiments, the system is configured to be retained at the location internal to the subject for greater than or equal to 1 hour and less than or equal to 365 days. In some embodiments, the system further comprises greater than or equal to 1 grams of the therapeutic agent contained within the reservoirs of the system. In some embodiments, the system further comprises less than or equal to 100 grams of the therapeutic agent contained within the reservoirs of the system. In some embodiments, the system further comprises greater than or equal to 0.01 grams of the therapeutic agent contained within each reservoir of the system. In some embodiments, the system further comprises less than or equal to 10 grams of the therapeutic agent contained within each reservoir of the system. In some embodiments, the therapeutic agent of the system is a first therapeutic agent and wherein the system further comprises at least a second therapeutic agent. In some embodiments, the system comprises two or more capsules, at least one capsule comprising one or more electronic components, at least one capsule comprising a power source in electronic communication with the one or more electronic components, a magnetic component and a tether operably linking the magnetic component to at least one of the two or more capsules, wherein the system is configured for extended residence at a location internal to a subject. Some aspects are generally related to methods. In some embodiments, the method is related to administering a therapeutic agent to a subject. In some embodiments, the method comprises administering at least two articles to the subject such that the at least two articles self-assemble at a location internal to the subject to form a drug delivery system, wherein each of the at least two articles comprises: a reservoir configured to receive a therapeutic agent, a magnetic component, and a tether operably linking the reservoir and the magnetic component. In some embodiments, the method further comprises retaining the system at the location internal to the subject for greater than or equal to 1 hour and less than or equal to 365 days. In some embodiments, the method further comprises measuring an impedance of the magnetic components of the system. In some embodiments, the method further comprises disassembling the system at the location internal to the subject by actuating an actuation mechanism of at least one of the articles of the system. In some embodiments, the method further comprises degrading the tether associated with the capsule and the magnetic component of at least one of the articles to release the system from the location internal to the subject. Some aspects are related to kits. In some embodiments, the kit comprises at least two articles for delivering a therapeutic agent to a location internal to a subject, wherein each of the articles comprises a reservoir, a magnetic component, and a tether operably linking the reservoir and the magnetic component. In some such embodiments, each of the articles of the kit is sized and adapted for ingestion such that the article resides at the location internal to the subject. In some embodiments, the kit comprises at least two articles for gastric sensing, wherein each of the articles comprises a capsule comprising an electronic component and / or a power source, a magnetic component, and a tether operably linking the reservoir and the magnetic component, wherein each of the articles is sized and adapted for ingestion such that the article resides at a location internal to a subject. In some embodiments, the kit comprises a first article for delivering a therapeutic agent to a location internal to a subject, comprising a reservoir, a magnetic component, and a first tether operably linking the reservoir and the magnetic component and a second article for gastric sensing, comprising a capsule comprising an electronic component and / or a power source, a magnetic component, and a second tether operably linking the reservoir and the magnetic component, wherein each of the articles is sized and adapted for ingestion such that the article resides at a location internal to a subject. Other advantages and novel features of the present disclosure will become apparent from the following detailed description of various non-limiting embodiments of the disclosure when considered in conjunction with the accompanying figures. In cases where the present specification and a document incorporated by reference include conflicting and / or inconsistent disclosure, the present specification shall control. BRIEF DESCRIPTION OF THE DRAWINGS Non-limiting embodiments of the present disclosure will be described by way of example with reference to the accompanying figures, which are schematic and are not intended to be drawn to scale unless otherwise indicated. In the figures, each identical or nearly identical component illustrated is typically represented by a single numeral. For purposes of clarity, not every component is labeled in every figure, nor is every component of each embodiment of the disclosure shown where illustration is not necessary to allow those of ordinary skill in the art to understand the disclosure. In the figures: FIGS. 1A-1E are schematic diagrams of articles and systems, according to some embodiments; FIG. 2A is a schematic diagram showing a conceptual framework relevant to the systems described herein, according to some embodiments; FIGS. 2B-2C show schematic diagrams and images of articles and systems, according to some embodiments; FIG. 2D is a schematic diagram showing how the articles and systems may be used, according to some embodiments; FIGS. 3A-3B are images of a system ex-situ and in-situ, according to some embodiments; FIGS. 3C-3D are plots detailing the concentration of a therapeutic agent in a subject and the weight of the subject as a function of time, according to some embodiments; FIG. 4A is a schematic diagram and optical images showing micro-outlets of a reservoir, according to some embodiments; FIGS. 4B-4D are plots detailing release of therapeutic agents as a function of time, according to some embodiments; FIGS. 4E-4G are optical images of tests and corresponding data collected therefrom of forces associated with articles, according to some embodiments; FIG. 4H is a Von Mise stress distribution of a single ISC system with a suture length of 20 mm and a five-stack ISC system with a suture length of 20 mm, according to some embodiments; FIG. 4I is a heat map of maximum contact pressure of the ISC system contacting the funnel while freely falling, according to some embodiments; FIG. 4J is a heat map of maximum stress inside the suture when the ISC system falls freely into a funnel that resembles a pylorus, according to some embodiments; FIG. 4K is a schematic diagram showing how data may be wireless transmitted from a location internal to a subject to external of the subject, according to some embodiments; FIGS. 4L-4N are a schematic diagram, an image, and data collected from articles comprising resistors, according to some embodiments; FIG. 5 shows plots of drug stability for various therapeutic agents, according to some embodiments; FIG. 6A are a series of images of articles and systems, according to some embodiments; FIG. 6B is an image of a funnel system used to test the articles and systems, according to some embodiments; FIG. 6C is a table showing the results obtained using the systems shown in FIG. 3A, according to some embodiments; FIG. 7 is a schematic diagram of the circuit board for the wireless resistor, according to some embodiments; FIG. 8A is a schematic diagram of the study design, according to some embodiments; FIG. 8B are images of a system add a location internal of a subject, according to some embodiments; FIG. 8C is a plot of the average residence time of a system add a location internal to a subject, according to some embodiments; FIG. 8D is a schematic diagram of an article, according to some embodiments; FIG. 8E shows images of a system at a location internal to the subject, according to some embodiments; FIG. 8F is an image of an article comprising a capsule, according to some embodiments; FIG. 8G is a schematic diagram of the reservoir containing an actuation device, according to some embodiments; FIG. 8H is a schematic diagram showing the degradation of a portion of an article, according to some embodiments; FIG. 8I is a schematic diagram of the disassembly of a system at the location internal to the subject, according to some embodiments; FIG. 8J are images of the degradation of a component of an article, according to some embodiments; FIG. 9A are images of a system comprising 3 articles at a location internal to a subject as a function of time, according to some embodiments; FIG. 9B shows images of a system at a location internal to a subject, according to some embodiments; FIGS. 9C-9D shows dissolution time of gelatine film with different thickness and dissolution time of isomalt pin to trigger actuation, according to some embodiments; FIG. 10A are plots showing a concentration of the therapeutic agent as a function of time in the blood of a subject, according to some embodiments; FIG. 10B is a table showing my concentration of therapeutic agent in the blood of a subject, according to some embodiments; FIG. 10C are plots of the weight of a subject as a function of time, according to some embodiments; FIGS. 11A-11B are images of a system at a location internal to a subject, according to some embodiments; FIGS. 12A-12E are schematic diagrams, images, and a plot detailing the safe passage of articles through at least a portion of a subject, according to some embodiments; FIGS. 13A-13D are schematic diagrams and images detailing the safe passage of articles through at least a portion of a subject, according to some embodiments; and FIG. 14 is a schematic diagram and images showing the safe passage of an article through at least a portion of a subject, according to some embodiments FIGS. 15A-15F show data associated with a long term gastric sensing system, according to some embodiments FIG. 16 is a schematic representation of a temperature and microphone sensor system, according to some embodiments FIGS. 17A-17C show detailed design specifications for the flexible printed circuit board (PCB) of the system shown in FIG. 15B, according to some embodiments FIG. 18 shows in vitro temperature measurements from both the commercial temperature sensor and a system, according to some embodiments; FIG. 19A-19B shows in vitro power consumption of a system, according to some embodiments; FIGS. 20A-20B are schematic diagrams of gastric sensing systems, according to some embodiments; FIGS. 21A-21B are a schematic diagrams shows different drug release mechanisms, according to some embodiments. DETAILED DESCRIPTION Some aspects disclosed herein are generally related to articles for delivering therapeutic agents to a location internal to a subject. In some embodiments, the articles may include a reservoir containing and / or configured to contain a therapeutic agent, a magnetic component (e.g., a magnet), and a tether linking the reservoir and the magnetic component. In some embodiments, a plurality of the articles may be ingested by a subject, and the magnetic component of the articles may self-assemble at a location internal of the subject to form a system for drug delivery and / or diagnostics (e.g., sensing). Advantageously, the reservoirs of the articles may contain a relatively large amount of a therapeutic agent (e.g., greater than or equal to 1 gram and less than or equal to 100 grams of therapeutic agent) in the system, in some embodiments. In some embodiments, the system may be configured to slowly release the therapeutic agent over a relatively long period of time (e.g., greater than or equal to 24 hours, greater than or equal to 365 days). In some embodiments, the system may be configured to monitor one or more physiological characteristics at a location internal to a subject (e.g., a location in a gastrointestinal tract of the subject). In some embodiments, the system may be configured to operate (e.g., via a sensor) over a relatively long period of time (e.g., greater than or equal to 24 hours, greater than or equal to 365 days). Still other aspects are related to methods of administering and using the articles and systems described herein, kits containing the same, or the like. Some aspects are generally related to systems including two or more articles. For instance, each article may include a capsule, a magnetic component, and a tether operably linking the capsule and the magnetic component. Following ingestion of two or more articles, the respective magnetic components of the articles may self assemble, thereby forming the system. In some embodiments, one or more of the capsules of the system is a reservoir configured to contain a therapeutic agent. In some embodiments, one or more of the capsules of the system is a reservoir comprising a therapeutic agent. In some embodiments, one or more of the capsules of the system is configured to contain one or more sensors. In some embodiments, one or more of the capsules of the system comprise one or more sensors. In some such embodiments, the system is configured as a gastric sensing system. Some aspects are related to related methods, uses, kits, or the like. Generally, patients are often instructed to follow a regimen regarding a therapeutic agent when receiving treatment, often times requiring the patient to adhere to the prescribed schedule over a long time. For example, a patient may take a tablet (e.g., a pill) containing the therapeutic agent once a day for 30 or more days to treat tuberculosis or other diseases. Such regimens for patients, however, may be difficult to adhere to over such long time due to varying schedules, socioeconomic statuses, and / or the quality of the medical team providing treatment, and failure to adhere to such a regimen may be detrimental to patient outcomes. Accordingly, some aspects of the present disclosure are related to articles and / or systems (e.g., systems comprising a plurality of articles as described herein) containing greater than or equal to 1 gram and less than or equal to 100 grams of a therapeutic agent and that are designed to control the release of the therapeutic agent over the course of greater than or equal to 1 hour and up to 365 days at a location internal to the subject. Advantageously, articles described herein may be individually ingested by a subject and deliver relatively small loads of therapeutic agent to a location internal to a subject, whereafter the articles may self-assemble into a drug delivery system that may be retained at the location internal to the subject for a relatively long time. The system may, in some embodiments, facilitate with a relatively slow release of the total payload of therapeutic agent present in the multiple articles comprising the drug delivery system, which may improve patient adherence to prescribed medication regimen. In some embodiments, the articles and / or systems described herein may be suitable for administering to a subject in need of treatment for Hepatitis C and / or tuberculosis. In some embodiments, advantageously, long-term monitoring of patient conditions may desirably improve tracking of certain physiological conditions and / or provide information for improved medical treatment. For example, continuous tracking of body temperature is invaluable, as it serves as a primary indicator for potential infections, offering higher precision when measured internally compared to external methods. Similarly, persistent cardiac activity monitoring is important for early detection of cardiovascular conditions, facilitating targeted preventive measures or optimized therapeutic interventions. Regular, ex-vivo, monitoring of patient conditions is similarly challenging as to adherence to therapeutic agent regimens due to varying schedules, socioeconomic statuses, and / or the quality of the medical team providing treatment to the patient. While in-vivo monitoring over long times may alleviate the challenges associated with ex-vivo monitoring, implementation of such sensing systems may require invasive internalization thereof and / or is complicated by short gastric residences times and high energy consumption of electronic sensing systems. Advantageously, the systems described herein facilitate internalization and retention of various electronic components. Such systems are configured for gastric sensing, which may facilitate continued and long-term, in-vivo monitoring of various patient conditions, without activity from the patient outside the initial internalization thereof. The systems described herein, in some embodiments, are configured facilitate long term retention and long term operation at a location internal the subject. Accordingly, such systems may lead to accurate biomonitoring and result in improved patient outcomes long term. Some aspects are related to articles for delivering a therapeutic agent to a location internal to a subject. In some embodiments, the article comprises a reservoir configured to receive a therapeutic agent, a magnetic component, and a tether operably linking the reservoir and the magnetic component. In some embodiments, multiple articles for delivering a therapeutic agent to a location internal a subject may self-assemble to form a system as described in more detail elsewhere herein. For example, as illustrated in FIG. 1A, article 100 comprises reservoir 110 and magnetic component 120. In some embodiments, reservoir 110 and magnetic component 120 are operably linked by tether 130. In some embodiments, as shown illustratively in FIG. 1B, an article 100 may comprise two or more reservoirs 110 each operably linked to magnetic component 120 by two or more tethers 130. While only two reservoirs and two tethers are shown in FIG. 1B, those of ordinary skill in the art would readily envision, based upon the teachings of this specification, that a plurality of reservoirs and / or plurality of tethers may be associated with a magnetic component. In some embodiments, each article comprises one or more reservoirs, two or more reservoirs, three or more reservoirs, four or more reservoirs, five or more reservoirs, six or more reservoirs, seven or more reservoirs, eight or more reservoirs, nine or more reservoirs, or up to ten reservoirs. In some embodiments, each article comprises one or more tethers (e.g., operably linking each reservoir to the magnetic component), two or more tethers, three or more tethers, four or more tethers, five or more tethers, six or more tethers, seven or more tethers, eight or more tethers, nine or more tethers, or up to ten tethers. In some embodiments, the number of reservoirs and tethers present in the article correspond such that each individual tether may operably link a corresponding reservoir to the magnetic component of the article. Additionally, in some embodiments, while depicted as cylindrically shaped, the components (e.g., magnetic component, reservoir, etc.) of the article may have any suitable shape for performing their function (e.g., a magnetic component providing a magnetic force, a reservoir containing a therapeutic agent) so long as the components maintain a size and / or shape suitable for ingestion, as described elsewhere herein. In some embodiments, a system (e.g., system 150 of FIG. 1D) comprises a plurality of articles (e.g., article 100 of FIG. 1A, FIG. 1B, and / or FIG. 1C). Each article may be the same or different and may comprise any suitable number of reservoirs and tethers. In an illustrative embodiment, and without wishing to be limited by such, exemplary system 150 as shown in FIG. 1D comprises five articles each comprising a reservoir 110, magnetic component 120, and tether 130 operably linking each reservoir 110 and magnetic component 120. In some embodiments, each article self-assembles via magnetic components 120 to form system 150 (e.g., at a location internal to a subject). In some embodiments, as described in more detail below, the article may further comprise a degradable linker. For example, as shown illustratively in FIG. 1C, article 100 comprises degradable linker 140 adjacent magnetic component 120 and adjacent reservoir 110, with each degradable linker 140 operably linked to tether 130. As used herein, when a component is referred to as being “adjacent” another component, it can be directly adjacent to (e.g., in contact with) the component, or one or more intervening components (e.g., polymeric materials, layers, coatings) may also be present. A component that is “directly adjacent” another component means that no intervening component(s) is present. While FIG. 1C shows a degradable linker adjacent to reservoir 110 and magnetic component 120, those of ordinary skill in the art would readily envision, based upon the teachings of this specification, that not each degradable linker necessarily need to be present. For example, in some embodiments, the article comprises a degradable linker adjacent the reservoir (e.g., but not the magnetic component). In some embodiments, the article comprises a degradable linker adjacent the magnetic component (e.g., but not the reservoir). In some embodiments, the article comprises a first degradable linker adjacent the magnetic component and a second degradable linker (e.g., the same or different than the first degradable linker) adjacent the reservoir. Each article may comprise one or more, two or more, or three or more types of degradable linkers. For example, in an illustrative embodiment, the article comprises a first linker configured for degradation at a first average degradation rate and a second linker configured for degradation at a second average degradation rate under the same conditions. In some embodiments, the linker degradation is pH dependent. In another illustrative embodiment, the article comprises a first linker configured for degradation under a first set of physiological conditions (e.g., in (1) acidic pH such as in the stomach or, (2) alternatively, in relatively neutral pH such as in the intestines, etc.) and a second linker configured for degradation under a second set of physiological conditions different than the first set of physiological conditions (e.g., (1) in relatively neutral pH such as in the intestines, or, alternatively, (2) acidic pH such as in the stomach, etc.). In some embodiments, the second linker is not configured for substantial degradation under the first set of conditions, thereby enabling selectable and partial degradation of the structure under select condition and / or in select locations within a subject (e.g., different positions along the G.I. track.) For example, in some cases, the second linker is not substantially degradable at a first physiological condition (e.g., in acidic pH such as in the stomach) and is configured for degradation at a second physiological condition different than the first set of physiological conditions. In some embodiments, where multiple linkers are present in the article and / or system as disclosed herein, each linker may have the same or different property (degradability, degradation rate, material selection, pH responsiveness) with respect to the other linkers. The term ‘physiological condition’ generally refers to a set of conditions of the external or internal milieu that occurs in an organism or cellular system (e.g., in contrast to laboratory conditions). For example, in some cases, a physiological condition ranges in temperature between about 20oC and about 40oC (e.g., between about 35oC and about 38oC) and / or atmospheric pressure of about 1 atm. In some embodiments, the physiological conditions are that of an internal organ such as the stomach, intestines, bladder, lungs, and / or heart. Each linker may be selected such that the linker dissolves, degrades, mechanically weakens, and / or mechanically separates from at least one of the one or more components (e.g., tether, magnetic component, reservoir) after a particular residence time period. The term residence time period generally refers to the length of time during which the article and / or system (or a component of the article and / or system) described herein resides at a location internally of a subject as measured from the time initially present in the location internally of the subject to the time at which the article and / or system (or such component of the article and / or system being referenced) no longer resides at the location internally of the subject due to, for example, degradation, dissolution, and / or exit of the article and / or system or such component(s) of the article and / or system being referenced from the location internally of the subject. In an illustrative embodiment, the article and / or system may be orally administered such that the article and / or system resides at a location internally of the subject such as the stomach above the pylorus and exits through the pylorus into the intestine (e.g., after degradation of at least a portion of the article and / or system), where the residence time period is measured as the length of time between when the article and / or system initially resides in the stomach and when the structure (or a component of the article and / or system being referenced) exits through the pylorus. Residence time periods are described in more detail, below. The term “subject," as used herein, refers to an individual organism such as a human or an animal. In some embodiments, the subject is a mammal (e.g., a human, a non-human primate, or a non-human mammal), a vertebrate, a laboratory animal, a domesticated animal, an agricultural animal, or a companion animal. In some embodiments, the subject is a human. In some embodiments, the subject is a rodent, a mouse, a rat, a hamster, a rabbit, a dog, a cat, a cow, a goat, a sheep, or a pig. In some embodiments, the location internal to the subject is the colon, the duodenum, the ileum, the jejunum, the stomach, or the esophagus. In an exemplary set of embodiments, the location internal to the subject is the stomach. As those of ordinary skill in the art will understand based upon the teachings of this specification, an article that is suitable for ingestion is generally biocompatible. The term “biocompatible," as used herein, generally refers to a material that does not invoke a substantial adverse reaction (e.g., deleterious immune response) from an organism or subject (e.g., a mammal), a tissue culture or a collection of cells, or invokes only a reaction that does not exceed an acceptable level. In some embodiments, the article may comprise a reservoir. In some embodiments, the article may comprise a plurality of reservoirs, for example, 2 reservoirs, 3 reservoirs, 4 reservoirs, and so forth. In some embodiments, the reservoir defines an interior volume. In some embodiments, the reservoir defines an interior volume configured to receive a therapeutic agent. In some embodiments, the reservoir defines an interior volume and comprises a therapeutic agent within the interior volume. For example, the reservoir may be configured to receive a therapeutic agent, in some embodiments, in its interior volume. In some embodiments, the reservoir may contain a therapeutic agent. In some embodiments, the article may comprise the therapeutic agent contained within the reservoir, for example, in the interior volume of the reservoir. In some embodiments, the interior volume of the reservoir may comprise an actuation mechanism, as described elsewhere herein. In some embodiments, the materials of the reservoir may be biocompatible. Additionally, in some embodiments, the materials of the reservoir may be configured to resist decomposing, corroding, or otherwise degrading when experiencing conditions similar to those present at a location internal to the subject, e.g., acidic conditions experienced in the stomach of the subject. Using materials for the reservoir that are resistant to degrading when at the location internal to the subject may allow for the delivery and retention of relatively large payloads of therapeutic agents, as described elsewhere herein, without a subject being exposed to the entirety of the payload In some embodiments, the reservoir defines an interior volume and comprises a gas, a liquid, and / or a solid within the interior volume. In some embodiments, the reservoir does not include an outlet (e.g., a micro-outlet, a nano-outlet), and may be configured to reside at a location internal the subject (e.g., within a system comprising two or more articles). In some embodiments, the reservoir may be configured within a system to reside at a location internal the subject to mitigate hunger of the subject and / or as a weight loss mechanism, e.g., due to the volume of space occupied by the system at the location internal to the subject. In some embodiments, it may be desirable for the reservoir to comprise the majority of the volume associated with the article such that a large amount of therapeutic agent may be contained within the reservoir(s) of the article to be ingested. In some embodiments, the volume of the reservoir accounts for greater than or equal to 30%, greater than or equal to 40%, greater than or equal to 50%, greater than or equal to 60%, greater than or equal to 70%, greater than or equal to 80%, greater than or equal to 90%, or greater than or equal to 95% of the volume of the article. In some embodiments, the volume of the reservoir accounts for less than or equal to 99%, less than or equal to 95%, less than or equal to 90%, less than or equal to 80%, less than or equal to 70%, less than or equal to 60%, less than or equal to 50%, or less than or equal to 40% of the volume of the article. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 30% and less than or equal to 99%). Other ranges are also possible. In some embodiments, the reservoir may be any suitable size and shape. In some embodiments, for example, the reservoir may be sized and shaped for administration to a subject, as described elsewhere herein. In some embodiments, the size of the reservoir is suitable for fitting within a container as described elsewhere herein. In some embodiments, the reservoir may have any suitable shape, e.g., such as a regular (e.g., cylindrical, cubic, spherical, rectangular, prism, etc.) or irregular shape. In some embodiments, the reservoir may have any suitable cross-section, such that the cross- section is regular (e.g., a square, a circle, a triangle, or any other regular polygon) or irregular. In some embodiments, the reservoir comprises at least one micro-outlet configured to release a therapeutic agent from the interior of the reservoir to an exterior of the reservoir (e.g., at a location internal to the subject). In some embodiments, the reservoir comprises a plurality of micro-outlets. In some embodiments, the reservoir comprises a single micro-outlet. In some embodiments, the reservoir comprises greater than or equal to 2 micro-outlets, greater than or equal to 3 micro-outlets greater than or equal to 4 micro-outlets greater than or equal to 5 micro-outlets greater than or equal to 6 micro-outlets, greater than or equal to 7 micro-outlets greater than or equal to 8 micro- outlets, greater than or equal to 9 micro-outlets, greater than or equal to 10 micro-outlets, greater than or equal to 20 micro-outlets, greater than or equal to 30 micro-outlets, greater than or equal to 40 micro-outlets, greater than or equal to 50 micro-outlets, greater than or equal to 75 micro-outlets, greater than or equal to 100 micro-outlets, greater than or equal to 200 micro-outlets, greater than or equal to 300 micro-outlets, or greater than or equal to 400 micro-outlets. In some embodiments, the reservoir comprises less than or equal to 500 micro-outlets, less than or equal to 400 micro-outlets, less than or equal to 300 micro-outlets, less than or equal to 200 micro-outlets, less than or equal to 100 micro-outlets, less than or equal to 75 micro-outlets, less than or equal to 50 micro-outlets, less than or equal to 40 micro-outlets, less than or equal to 30 micro- outlets, less than or equal to 20 micro-outlets, less than or equal to 10 micro-outlets, less than or equal to 9 micro-outlets, less than or equal to 8 micro-outlets, less than or equal to 7 micro-outlets, less than or equal to 6 micro-outlets, less than or equal to 5 micro- outlets, less than or equal to 4 micro-outlets, or less than or equal to 3 micro-outlets. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 2 micro- outlets and less than or equal to 500 micro-outlets). Other ranges are also possible. It will be understood that the number of micro-outlets present may be selected based on the total desired surface area associated with the micro-outlets, as the surface area may be associated with the release rate of a therapeutic agent from the reservoir. It is possible for differently sized micro-outlets to be present on the reservoir, in accordance with some embodiments. Each micro-outlet of the reservoir may have any suitable cross-sectional shape, in accordance with some embodiments. In some embodiments, the cross-sectional shape of a reservoir is regular, e.g., a square, a circle, a triangle, or any other regular polygon. In some embodiments, the shape of a reservoir is irregular. It is possible for differently shaped micro-outlets to be present on the reservoir, in accordance with some embodiments. The cross-sectional dimension of each micro-outlet need not be uniform across a length of the micro-outlet. For example, in some embodiments, the micro-outlet may comprise a taper (e.g., a change in cross-sectional dimension and / or cross-sectional shape along a length of the micro-outlet). In some such embodiments, the therapeutic agent moving from the interior to the exterior of the reservoir may constitute delivering a therapeutic agent at the location internal to the subject. In some embodiments, the micro-outlet may be relatively small, for example, relative to the dimensions of the article, to facilitate a slow release of an entity within the reservoir to your location external of the reservoir. In some embodiments, the micro-outlet is configured to slowly release a therapeutic agent from the reservoir at a location internal to the subject. In some embodiments, each micro-outlet may have a maximum cross-sectional dimension. A maximum cross-sectional dimension may refer to a width and / or a depth of the micro-outlet, in some embodiments. In some embodiments, the maximum cross- sectional dimension of each micro-outlet is less than or equal to 10 millimeter, less than or equal to 5 millimeter, less than or equal to 1 millimeter, less than or equal to 500 microns, less than or equal to 300 microns, less than or equal to 200 microns, less than or equal to 100 microns, less than or equal to 50 microns, less than or equal to 20 microns, less than or equal to 10 microns, less than or equal to 5 microns, less than or equal to 1 micron, less than or equal to 0.5 microns, less than or equal to 0.1 microns, or less than or equal to 0.01 microns. In some embodiments, the maximum cross-sectional dimension of the micro-outlet is greater than or equal to 0.001 microns, greater than or equal to 0.01 microns, greater than or equal to 0.1 microns, greater than or equal to 0.5 microns, greater than or equal to 1 micron, greater than or equal to 5 microns, greater than or equal to 10 microns, greater than or equal to 20 microns, greater than or equal to 50 microns, greater than or equal to 100 microns, greater than or equal to 200 microns, greater than or equal to 300 microns, greater than or equal to 500 microns, greater than or equal to 1 millimeter, or greater than or equal to 5 millimeters. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 0.001 microns and less than or equal to 1 millimeter). Other ranges are also possible. While much of the description herein is generally directed to “micro-outlets”, those of ordinary skill in the art would understand that such outlets are not necessarily limited to dimensions on the order of microns and may have a cross-sectional dimension of sub-micron size (e.g., nano-outlets) such as a cross-sectional dimension of greater than or equal to 0.001 microns and less than or equal to 1 micron, or other ranges, as described above. In some embodiments, the reservoir comprises a plurality of micro-outlets. In some embodiments, a total cross-sectional area of all of the micro-outlets of a reservoir is greater than or equal to 10-6microns2, greater than or equal to 10-5microns2, greater than or equal to 10-4microns2, greater than or equal to 10-3microns2, greater than or equal to 10-3microns2, greater than or equal to 10-1microns2, greater than or equal to 1 microns2, greater than or equal to 10 microns2, greater than or equal to 102microns2, greater than or equal to 103microns2, greater than or equal to 104microns2, greater than or equal to 105microns2, greater than or equal to 106microns2, or greater than or equal to 107microns2. In some embodiments, the total cross-sectional area of all of the micro-outlets of a reservoir is less than or equal to 108microns2, less than or equal to 106microns2, less than or equal to 104microns2, less than or equal to 102microns2, less than or equal to 1 microns2, less than or equal to 1-2microns2, or less than or equal to 1-4microns2. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 10-6microns2and less than or equal to 108microns2). Other ranges are also possible. The article may comprise a magnetic component, in some embodiments. In some embodiments, the magnetic component comprises a magnet. In some such embodiments, the magnetic component may be contained within a container. As described elsewhere herein, the magnetic component of the article may facilitate the self-assembly by stacking of multiple articles to form a system. In some such embodiments, the formation of such systems may retention of relatively large amounts of therapeutic agent for long times at the location internal to the subject. According to some embodiments, the magnetic component may be associated and / or comprise a resistor. In some such embodiments, the resistor may facilitate the measuring of the impedance across the magnetic component, even at the location internal to the subject. In some embodiments, the article may further comprise one or more electronic components to facilitate wireless data transmission from the article at the location internal to the subject to a receiver that is external to the subject. In some embodiments, as described elsewhere herein in more detail, the presence of multiple articles comprising magnetic components may lead to the formation of a system comprising a stack of articles wherein the magnetic components are stacked (e.g., aggregated). In some embodiments, when multiple articles comprising magnetic components self-assemble to form a stack of magnetic components, one of the magnetic components comprises and / or is associated with a resistor configured to measure the impedance across the magnetic component. In some such embodiments, the impedance measured at the resistor may vary based on the number of magnetic components stacked in the system, which may provide information regarding the self-assembly of the articles into a system at the location internal to the subject. In some embodiments, the article may comprise a tether, for example, linking the magnetic component and the reservoir(s). For instance, referring again to FIG. 1A, article 100 comprises reservoir 110 operably linked to magnetic component 120 by tether 130. Any of a variety of materials may be suitable for use as the tether, in some embodiments. In some embodiments, the tether may comprise biocompatible polymers (e.g., polylactic acid, polypropylene, polyester, etc.) and / or metals (e.g., stainless steel). In some embodiments, the materials of the tether may be biocompatible. Accordingly, in some embodiments, the tether may comprise of a suture, a metal, an inorganic material, and / or polymeric material. In some embodiments, the tether may be elastic. In other embodiments, the tether may be substantially inelastic. In some embodiments, the tether may have a length that facilitates a system comprising multiple articles to have dimensions that prevent passage through a subject, as described elsewhere herein. In some embodiments, the length of the tether is less than or equal to 5 cm, less than or equal to 4 cm, less than or equal to 3 cm, less than or equal to 2.5 cm, less than or equal to 2 cm, less than or equal to 1.5 cm, less than or equal to 1 cm, or less than or equal to 0.5 cm. In some embodiments, the length of the tether is greater than or equal to 0.1 cm, greater than or equal to 0.5 cm, greater than or equal to1 cm, greater than or equal to 1.5 cm, greater than or equal to 2 cm, greater than or equal to 2.5 cm, greater than or equal to 3 cm, or greater than or equal to 4 cm. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 0.1 cm and less than or equal to 3 cm). Other ranges are also possible. The selection of a particular characteristic of the tether (e.g., length, material, degradability), in some embodiments, may be selected based on the location internal to the subject in which it is desirable to retain the article. For example, in an exemplary set of embodiments, the location internal to the subject is the stomach and the tether may have a length such that, upon multiple articles joining together, the cross-sectional dimension of the assembled system (e.g., comprising two or more articles) is too large to pass through the pylorus of the subject. In some embodiments, the characteristics of the tether (e.g., material, length, degradability) may be selected based on the identity of the subject, the therapeutic being administered, and / or the disease being treated. In some embodiments, wherein multiple tethers are present in the article and / or system as disclosed herein, each tether may have a length in accordance with the foregoing ranges. In some such embodiments, the length of some and / or all of the tethers present may be the same. In other such embodiments, the length of each tether may differ. In some embodiments, each tether is the same or different (e.g., having the same or differing characteristics such as length, degradability, degradation rate, material). Those of ordinary skill in the art would be capable of selecting other suitable characteristics of the tethers based upon the teachings of this specification. In some embodiments, the tether may be degradable. In some embodiments, the tether may be biodegradable and / or may be configured to degrade over a period of time when exposed to conditions encountered at the location internal to the subject. Advantageously, depending on the rate of degradation of the tether when the tether is degradable, the disassembly of the article (e.g., and systems comprising the article as described elsewhere here in) may be controlled based on the degradation of the tether and the subsequent release of the magnetic component and / or reservoir from the article and thus the location internal to the subject. Still, in other embodiments, the tether may not be substantially degradable (e.g., under typical physiological conditions). In some such embodiments, there may be other components of the article that may facilitate the disassembly of the article. For example, in some embodiments, a component adjacent the tether and reservoir (and / or magnetic component) may be degradable such that a connection between the tether and the reservoir (and / or magnetic component) degrades. In some embodiments, wherein the tether is not degradable (e.g., under physiological conditions), there may be a degradable linker that is a portion of the reservoir and / or a portion of the magnetic component. For instance, consider FIG. 1C, which is a schematic diagram of an exemplary article 100. The article 100 comprises reservoir 110 linked to magnetic component 120 by tether 130, where tether 130 is linked to the degradable portion 140 of the reservoir 110 and of the magnetic component 120. In some embodiments, the degradable linker of the reservoir comprises the portion of the reservoir that is linked to the tether. In some embodiments, the degradable linker of the magnetic component comprises the portion of the magnetic component that is linked to the tether. Accordingly, in some embodiments, that degradable linker operably links the tether to the reservoir. In a similar manner as to when the tether is degradable, the degradable portion of the reservoir may have a predictable degradation timeline, which may allow for disassembly of the article via the degradation of the degradable portion of the reservoir on a known timeline. In some embodiments, whether the tether is degradable and / or the magnetic component and / or reservoir contain a degradable portion, the degradable aspect may be associated with conditions encountered by the article at the location internal to the subject. In some such embodiments, degradation of the tether and or the degradable portion may occur on an expected timeline. In some embodiments, the degradable tether and / or the degradable portion of the magnetic component and / or reservoir may be configured to degrade when exposed to a catalyst. Those of ordinary skill in the art will be able to select suitable materials for the degradable portion and / or the degradable tether. For example, that the degradable tether and / or the degradable portion of the magnetic component and / or reservoir may be triggered to degrade by the subject ingesting an alkaline solution. In certain embodiments, the tether and / or linker (e.g., degradable linker) comprises a material such that, under relatively neutral pH physiological conditions (e.g., such as those in the duodenum), the tether and / or linker can be mechanically broken (i.e., mechanical failure) by a tensile force less than or equal to about 2 N within less than or equal to about 48 hours, or within less than or equal to about 24 hours under said neutral pH physiological conditions. In some embodiments, the mechanical failure occurs within the tether and / or linker material itself, and not at the interface between the tether and / or linker and the one or more polymeric components. Non-limiting examples of suitable tether and / or linker (e.g., degradable linker) materials include polyesters - such as including but not limited to, polycaprolactone, poly(propylene fumarate), poly(glycerol sebacate), poly(lactide), poly(glycol acid), poly(lactic-glycolic acid), polybutyrate, and polyhydroxyalkanoate; polyethers –such as including but not limited to, poly(ethylene oxide) and poly(propylene oxide); polyamides - such as including but not limited to, poly(caprolactam); polyvinyl alcohols; polyoxetanes; polyacrylates / methacrylates – such as including but not limited to, poly(methyl methacrylate) and poly(ethylene-co-vinyl acetate); polyanhydrides; and polyurethanes. In certain embodiments, the tether and / or linker (e.g., and / or degradable linker) comprises an ethyl acrylate, a methyl methacrylate and / or a low content of methacrylic acid ester with quaternary ammonium groups. In some embodiments, the tether and / or linker comprises a water soluble polymer such as vinylpyrrolidone-vinyl acetate copolymers (e.g., KOLLIDON® VA 64 (BASF) and KOLLIDON® SR), polyvinylpyrrolidone, cellulose acetate, hydroxypropyl methyl cellulose, or polyvinyl alcohol. In some embodiments, the tether and / or linker (e.g., a degradable linker) comprises a blend of polymers. In an exemplary embodiment, the linker comprises an isocyanate crosslinked polyurethane generated from low-molecular weight polycaprolactone monomers. In certain embodiments, the tether and / or linker (e.g., degradable linker) comprises an enteric polymer. In some embodiments, the tether and / or linker comprises an enteric elastomer. The term enteric is generally used to describe materials that are stable at relatively highly acidic pH conditions (e.g., pH of less than about 5.5) and susceptible to dissolution at relatively alkaline pH conditions (e.g., pH of between about 6 and about 9). In some embodiments, the enteric polymer includes, but is not limited to, cellulose acetate phthalate (CAP), hypromellose (INN) hydroxypropyl methylcellulose (HPMC), and / or poly(methacrylic acid-co-ethyl acrylate) (e.g., EUDRAGIT® a available from Evonik Industries AG (Essen, Germany)). In some embodiments, the dissolution of an enteric polymer can be triggered by, for example, ingestion of an alkali solution. In some embodiments, the enteric polymer has the capacity for dissolution between pH 4-8. According to some embodiments, the enteric polymer is selected such that the enteric polymer is stable in an acidic gastric environment (i.e., having a pH 1 to pH 4) but dissolves in a more alkali region of the gastrointestinal tract distal to the pylorus (i.e., having a pH greater than 5.5) and can serve as a tether. For example, in certain embodiments, the enteric polymer does not substantially degrade at a pH ranging between about 1 and about 5. In some embodiments, the enteric polymer does not substantially degrade at a pH of at least about 1, at least about 2, at least about 3, at least about 4, or at least about 4.5. In certain embodiments, the enteric polymer does not substantially degrade at a pH of less than or equal to about 5, less than or equal to about 4.5, less than or equal to about 4, less than or equal to about 3, or less than or equal to about 2. Any and all closed ranges that have endpoints within any of the above reference ranges are also possible (e.g., between about 1 and about 4.5, between about 1 and about 5, between about 1 and 4). Other ranges are also possible. In certain embodiments, the enteric polymer degrades substantially at a pH ranging between about 4 and about 8. In some embodiments, the enteric polymer degrades substantially at a pH of at least about 4, at least about 5, at least about 6, at least about 6.5, at least about 7, or at least about 7.5. In certain embodiments, the enteric polymer degrades substantially at a pH of less than or equal to about 8, less than or equal to about 7.5, less than or equal to about 7, less than or equal to about 6.5, less than or equal to about 6, or less than or equal to about 5. Any and all closed ranges that have endpoints within any of the above reference ranges are also possible (e.g., between about 4 and about 8, between about 5 and about 8, between about 6.5 and about 7.5). Other ranges are also possible. In some embodiments, an article comprising a reservoir, the reservoir comprising a dissolution liquid (e.g., suitable for dissolution of the degradable tether and / or degradable linker) may be administered to a subject (e.g., after a suitable residence time of the system) such that the dissolution liquid is released from the reservoir and interacts with the degradable tether and / or degradable linker (e.g., thereby dissolving at least a portion of the tether and / or linker). As such, in some embodiments, exit of the system from the subject may be controlled by administration of one or more liquids or reagents to the subject (e.g., via oral administration of an article as described herein). In some embodiments, the article comprises an actuation mechanism. In some embodiments, the actuation mechanism comprises a spring, an osmotic agent, a liquid configured to disassemble the system, and / or a swelling agent. For example, in some embodiments, an actuation mechanism may be configured to modulate a release rate of a therapeutic agent from a reservoir of an article. As another example, in some embodiments, an actuation mechanism of the article may facilitate disassembly of the article (e.g., and / or a system comprising the article(s), as described elsewhere herein). In some embodiments, the article may comprise an actuation mechanism configured to disassemble the article. In some embodiments, the actuation mechanism may comprise a spring, an osmotic agent, and / or a swelling agent configured to disassemble the article. In some embodiments, the actuation mechanism may comprise a spring configured to disassemble the article. In some embodiments, the actuation mechanism may be present in a reservoir of the article. In some such embodiments, the actuation mechanism, when actuated, may facilitate the release of a liquid configured to disassemble the article or a system comprising the article. In some embodiments, a separate container containing an actuation mechanism for disassembly of an article and / or system may be administered to a patient at a separate time than when the article and / or system is initially administered. As a non-limiting example, in some embodiments, two or more articles may be administered to a subject at a first time and / or a second time, where the two or more articles self-assemble to form a system at a location internal to the subject. At a third time, after the first time and / or second time, a container containing an actuation mechanism (e.g., a liquid configured to disassemble the system) may then be administered to the subject, the actuation mechanism may be activated, and the system disassembled such that it may exit the location internal the subject. Some aspects are generally related to articles for sensing, e.g., gastric sensing. In some embodiments, one or more articles interact (e.g., self-assemble) and / or form a system. For instance, in some embodiments, one or more articles form a gastric sensing system. In some embodiments, the system comprises one or more articles comprising two or more capsules. In some embodiments, the system comprises two or more capsules. As a nonlimiting example, in some embodiments, a system comprises a first article and a second article, where the first article comprise a capsule comprising one or more sensors and the second article comprises a reservoir containing a therapeutic agent. It should be understood that other embodiments are also possible. For example, as illustrated in FIG. 1E, article 101 comprises capsule 111 and magnetic component 120. In some embodiments, capsule 111 and magnetic component 120 are operably linked by tether 130. In some embodiments, an article may comprise two or more capsules each operably linked to magnetic component by two or more tethers. While only one capsule and tether are shown in FIG. 1E, those of ordinary skill in the art would readily envision, based upon the teachings of this specification, that a plurality of capsules and / or tethers are also possible. In some embodiments, the article comprises a capsule, e.g., for gastric sensing. In some embodiments, the article comprises a plurality of capsules, for example, 2 capsules, 3 capsules, 4 capsules, or more. In some embodiments, the article comprises two or more capsules. In some embodiments, the capsules define an interior volume, where the capsule is configured to receive an electronic component, such as one or more sensors, a power source, amongst others. Other electronic components are also possible. For example, in some embodiments, the capsule is configured to receive one or more sensors in its interior volume. In some embodiments, the capsule contains one or more sensors in its interior volume. In some embodiments, the article comprises the one or more sensors within the capsule, for example, in the interior volume defined by the capsule. In some embodiments, an actuation mechanism is present within the interior volume of the capsule, as described elsewhere herein. In some embodiments, a system comprises a plurality of articles (e.g., article 100 of FIG. 1A, FIG. 1B, and / or FIG. 1C and / or article 101 of FIG. 1E). Each article may be the same or different and may comprise any suitable number of reservoirs, capsules, sensors, and / or tethers. In some embodiments, the materials of a capsule are biocompatible. In some embodiments, the materials of the capsule may be configured to resist decomposing, corroding, or otherwise degrading when experiencing conditions similar to those present at a location internal to the subject, e.g., physiological conditions such as acidic conditions experienced in the stomach of the subject. In some embodiments, the capsule may be configured to receive and / or comprise one or more electronic components. Accordingly, in some embodiments where the capsule is configured to resist decomposing, corroding, or otherwise degrading, the capsule may provide an interior volume in which an electronic component may be housed having different conditions than conditions outside of the capsule (e.g., physiological conditions). In some embodiments, using materials for the capsule that are resistant to degrading when at the location internal to the subject allows for the delivery and retention of the capsules, e.g., once articles comprising the capsule self-assemble into a system configured to be retained at the location internal the subject, as described elsewhere herein. In some embodiments, it may be desirable for the interior volume of the capsule to comprise the majority of the volume associated with the article. In some embodiments, a large interior volume of the capsule may accommodate one or more sensors and / or multiple other electronic components that may beneficially improve performance of the article or an electronic component thereof, e.g., at a location internal the subject. In some embodiments, the interior volume of the capsule accounts for greater than or equal to 30%, greater than or equal to 40%, greater than or equal to 50%, greater than or equal to 60%, greater than or equal to 70%, greater than or equal to 80%, greater than or equal to 90%, or greater than or equal to 95% of the volume of the article. In some embodiments, the interior volume of the capsule accounts for less than or equal to 99%, less than or equal to 95%, less than or equal to 90%, less than or equal to 80%, less than or equal to 70%, less than or equal to 60%, less than or equal to 50%, or less than or equal to 40% of the volume of the article. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 30% and less than or equal to 99%). Other ranges are also possible. In some embodiments, one or more capsule of the article is sized to contain one or more power sources and / or electronic components. In some embodiments, one or more capsules contains one or more power sources and / or electronic components. In some embodiments, a capsule has a low permeability to water vapor and / or permeance to water. Accordingly, in some embodiments, the capsule is configured to maintain a relative humidity therein at any of a variety of suitable levels, e.g., to facilitate functioning of one or more power sources and / or electronic components contained therein and / or to avoid degradation of the one or more power sources and / or electronic components. In some embodiments, the capsule is configured to maintain a relative humidity within an interior volume defined by the capsule of less than or equal to 80%, less than or equal to 70%, less than or equal to 60%, less than or equal to 50%, or less than or equal to 40% for at least 1 hour, at least 1 day, at least 5 days, at least 10 days, at least 30 days, at least 60 days, at least 90 days, at least 120 days, at least 150 days, at least 180 days, at least 210 days, at least 240 days, at least 264 days, at least 270 days, at least 300 days, and / or up to 365 days when the capsule is at a location internal to the subject. According to some embodiments, the capsule may be configured to maintain the relative humidity therein at less than or equal to 60% for up to 365 days when the capsule is at a location internal to the subject. In some embodiments, the ability of the capsule to maintain a relative humidity therein may be tested using a humidity sensor contained within the capsule. In some embodiments, the one or more capsules of the article is associated with and / or comprises a power source. The power source may include any appropriate material(s), such as one or more batteries, photovoltaic cells, etc. In some embodiments, the power source comprises a battery. Non-limiting examples of suitable batteries include Li-polymer (e.g., with between 100 and 1000 mAh of battery life), Li-ion, nickel cadmium, nickel metal hydride, silver oxide, or the like. In some embodiments, the power source is rechargeable. In some embodiments, the power source comprises a rechargeable battery. In some embodiments, power source may be configured to be wirelessly recharged (e.g., via inductive charging). For example, in some embodiments, an article including a power source may be administered toa subject, whereafter the power source of the article may be wirelessly recharged while at the location internal to the subject (i.e., with the charger being external to the subject). In some cases, the battery is configured to provide power to one or more electronic components contained within the same capsule as the power source and / or contained in a capsule other than the one containing the power source. It will be understood that a first capsule may contain a power source and a second capsule may contain one or more electronic components, where the power source and electronic components are in electronic communication. In some embodiments, more than one capsule may contain a power source, which may provide a power supply sufficient for long term operation and / or monitoring using the systems. In some embodiments, the article further comprises an electronic component. For instance, in some embodiments, one or more capsules of the article contain an electronic component. In some embodiments, each of the one or more capsules is configured to contain a suitable number of electronic components. In some embodiments, each capsule contains a suitable number of electronic components. A suitable number of electronic components, in some embodiments, is greater than or equal to one, greater than or equal to two, greater than or equal to three, and so forth up, until a desired function of the electronic components is facilitated and / or the interior volume of the capsule is substantially filled such that no other electronic components may be contained therein. Electronic components may be any suitable electronic component known to the skilled artisan. In some embodiments, the article may comprise an electrical system. In some embodiments, an electrical system may include two or more electronic components. For instance, in some embodiments, the electrical system comprises a power source (e.g., a battery as described above), an actuator such as an electrical actuation control system, a microcontroller, a PCB, a wireless component, a central processor, a power management system, a system wakeup controller, and / or one or more electronic sensors such as temperature sensors, a microphone, and / or humidity sensors. In some embodiments, the electronic component comprises a temperature sensor. In some embodiments, the electronic component comprises a microphone. In some embodiments, the electronic component comprises a pH sensor. In some embodiments, the electronic component comprises a carbon dioxide sensor. In some embodiments, the electronic component comprises an accelerometer. In some embodiments, the electronic component comprises an oxygen sensor. In some embodiments, the electronic component comprises a hydrogen sulfide sensor. In some embodiments, the electronic component comprises a pressure sensor. In some embodiments, where the electronic component comprises a sensor (e.g., a temperature sensor, a pressure sensor, an oxygen sensor, etc.), the sensor is configured to operate within a liquid, e.g., at physiological conditions. In some embodiments, the article comprises a wireless communication component. In some embodiments, the article comprises an antenna associated with the one or more electronic components. In some embodiments, the antenna associated with the one or more electronic components is configured to receive a wireless signal. In some embodiments, upon receipt of the wireless signal, the electronic component may perform a function (e.g., measures a pH, measures a temperature, etc.). For example, in some embodiments, receipt of a wireless signal triggers the measurement of a temperature at a location internal the subject. In some embodiments, receipt of the wireless signal by one or more electronic components in a capsule may trigger and / or alter release of a therapeutic payload in the capsule and / or reservoir. For instance, in some embodiments, a system may be configured to receive a wireless signal at a first capsule, and the first capsule is in wireless and / or electronic communication with a triggerable drug release reservoir. Accordingly, in some embodiments, an article or system comprises a triggerable drug release reservoir in electronic and / or wireless communication with the at least one capsule. In some embodiments, receipt of a wireless signal may facilitate coordination of one or more electronic components of the article or system. In some embodiments, a first capsule is configured to send a wireless signal and a second capsule is configured to receive the wireless signal, such that the first capsule is a master device and the second capsule is a slave device. Accordingly, in some embodiments, two or more capsules are in wireless and / or electronic communication. In some embodiments, a master device external the subject (e.g., a smartphone) is configured to send a wireless signal to a slave device internal the subject (e.g., a capsule). In some embodiments, the one or more electronic components are in electrical communication with another component of the article or system. For example, in some embodiments, an electronic component of a first capsule may be in electronic communication with a power source of the first capsule. As another example, in some embodiments, an electronic component of a first capsule may be in electronic communication with a power source of the second capsule. As another example, in some embodiments, an electronic component of a first capsule may be in electronic communication with an electronic component of the second capsule. Any electronic component circuitry may be implemented by any suitable type of analog and / or digital circuitry. For example, the electronic component circuitry may be implemented using hardware or a combination of hardware and software. When implemented using software, suitable software code can be executed on any suitable processor (e.g., a microprocessor) or collection of processors. The one or more electronic components can be implemented in numerous ways, such as with dedicated hardware, or with general purpose hardware (e.g., one or more processors) that is programmed using microcode or software to perform the functions recited above. In this respect, it should be appreciated that one implementation of the embodiments described herein comprises at least one computer-readable storage medium (e.g., RAM, ROM, EEPROM, flash memory or other memory technology, or other tangible, non-transitory computer-readable storage medium) encoded with a computer program (i.e., a plurality of executable instructions) that, when executed on one or more processors, performs the above-discussed functions of one or more embodiments. In addition, it should be appreciated that the reference to a computer program which, when executed, performs any of the above-discussed functions, is not limited to an application program running on a host computer. Rather, the terms computer program and software are used herein in a generic sense to reference any type of computer code (e.g., application software, firmware, microcode, or any other form of computer instruction) that can be employed to program one or more processors to implement aspects of the techniques discussed herein. In some embodiments, the one or more electronic components are connected to the article using one or more techniques known to those skilled in the art. For example, in some embodiments the one or more electronic components are mechanically pressfit into the capsule of the article. In other embodiments, the one or more electronic components are connected to the drug delivery article using a bonding method. In some embodiments the bonding method is any suitable bonding method known to those of skill in the art. For example, in some embodiments the bonding method comprises chip bonding. In other embodiments, the bonding method comprises wire-tacking adhesives. In some embodiments, the bonding method comprises potting an encapsulation. Without wishing to be bound by any particular theory, potting is a method known in the art that comprises the filling small spaces or services with the material that will protect components from physical and environmental damage. Typical resins used for potting include epoxies and silicones, some of which may be UV-curing formulations. Other resins are also possible. In some embodiments, encapsulation comprises casting and / or molding electronic component using similar resins as described above. In some embodiments, the bonding method uses an adhesive. In some embodiments, the adhesive comprises an electrically conductive adhesives, a thermally conductive adhesives, or an UV-curing adhesives. Other adhesives are also contemplated in some embodiments, for example, cyanoacrylates, silicone resins, and polyimides. Gastric sensing systems, in some embodiments, comprise low power battery and signaling systems. As would be understood by those of ordinary skill in the art, data sent over a wireless medium are generally important as, in some embodiments, the data comprises a user’s (and / or patient’s) private health information. In some cases, a command can invoke the operation of the ingestible device that directly affects the user’s health such as a therapeutic does. Advantageously, the systems and methods described herein may provide, in some embodiments, secure communication such that only authorized users and / or medical professionals can read sensor data and / or send valid commands to a system. Advantageously, the system and methods described herein may provide, in some embodiments, an energy-efficient security protocol to further improve the wireless communication (e.g., of an ingestible and / or implantable article). In some embodiments, the security protocol advantageously provides data encryption to protect sensor and command information and mutual authentication to prevent unauthorized access to both ingestible and external devices. In some embodiments, the security protocol uses low energy by, at least in part, adopting Speck, a lightweight block cipher that is optimized for software implementation, and symmetric challenge-response protocol as a base protocol. In some embodiments, articles comprising one or more capsules further include a magnetic component and / or a tether operably linking the one or more capsules to the magnetic component. Magnetic components and tethers are described elsewhere herein in more detail. For instance, in some embodiments, an article comprises a capsule operably linked to a magnetic component via a tether. As another nonlimiting example, in some embodiments, an article comprises a first capsule operably linked to a magnetic component via a first tether and a second capsule operably linked to the magnetic component via a second tether. Another nonlimiting embodiment includes an article comprising a capsule operably linked to a magnetic component via a first tether and a reservoir containing a therapeutic agent operably linked to the magnetic component via a second tether. In some embodiments, an article containing a capsule and a reservoir may be configured to form a closed feedback loop. For instance, in some embodiments, a capsule contains a sensor configured to sense a condition of a patient and to communicate with one or more other electronic components contained in the article or in a second article to provide feedback and to modulate a release rate of a therapeutic agent from the reservoir, e.g., via an actuation mechanism. In some embodiments, the article (e.g., for sensing and / or for delivering a therapeutic agent) is sized and adapted for ingestion. In some embodiments, as described elsewhere herein, the article may be sized and adapted such that it resides at the location internal to the subject. In some such embodiments, residence at the location internal to the subject may occur due to the presence of two or more articles. In some embodiments, the article further comprises a container containing the reservoir, capsule, magnetic component, and / or tether. In some embodiments, the article further comprises a container containing the capsule, magnetic component, and tether. In some embodiments, the article may further comprise a container containing the reservoir, magnetic component, and tether. The container, in some embodiments, may comprise biocompatible materials that may be designed to degrade and / or dissolve following ingestion of the article comprising the container. For example, in some embodiments, the container may comprise a sugar and / or a gel. In some embodiments, degradation and / or dissolution of the container may facilitate release of the remaining components of the article from the container. In some embodiments, the container may be sized and adapted for ingestion. For example, in some embodiments, the container may be sized such that in line with FDA- approved products for endoscopy systems and / or pills. For example, in some embodiments, the largest dimension of the article and / or the container of the article (e.g., a length, a width, or a thickness) is less than or equal to 25 mm, less than or equal to 22 mm, less than or equal to 20 mm, less than or equal to 18 mm, less than or equal to 15 mm, less than or equal to 12 mm, less than or equal to 10 mm, less than or equal to 9 mm, or less than or equal to 8 mm. In some embodiments, the largest dimension of the article and / or container of the article may be related to a maximum cross-sectional area of the article. In some embodiments, the maximum cross-sectional area of the article is greater than or equal to 10 mm2, greater than or equal to 25 mm2, greater than or equal to50 mm2, greater than or equal to 75 mm2, greater than or equal to 100 mm2, greater than or equal to 150 mm2, greater than or equal to 200 mm2, greater than or equal to 250 mm2, greater than or equal to 300 mm2, greater than or equal to 350 mm2, greater than or equal to 400 mm2, greater than or equal to 450 mm2, or greater than or equal to 500 mm2. In some embodiments, the maximum cross-sectional area of the article is less than or equal to 550 mm2, less than or equal to 500 mm2, less than or equal to 450 mm2, less than or equal to 400 mm2, less than or equal to 350 mm2, less than or equal to 300 mm2, less than or equal to 250 mm2, less than or equal to 200 mm2, less than or equal to 150 mm2, less than or equal to 100 mm2, less than or equal to 75 mm2, less than or equal to 50 mm2, or less than or equal to 25 mm2. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 10 mm2and less than or equal to 550 mm2). Other ranges are also possible. In some embodiments, the dimensions of the article and / or the container of the article correspond or are smaller than a 000-sized pill. In some embodiments, the dimensions of the container correspond or are smaller than a 00-sized pill. In some embodiments, sizes of the capsule corresponding to smaller pill sizes may be desirable to facilitate ingestion of the pill by a subject, e.g., by swallowing. However, larger sizes (e.g., corresponding to 000- or 00- pill sizes) may facilitate the inclusion of larger components and / or additional components of the article, e.g., a larger reservoir, capsule, electronic components, magnetic component, tether, an actuation mechanism, etc. For example, based on the application, a container may be manufactured to particular specifications or a standard size, including, but not limited to, a 000, 00, 0, 1, 2, 3, 4, and 5, as well as larger veterinary capsules Su07, 7, 10, 12el, 11, 12, 13, 110ml, 90ml, and 36ml. In some embodiments, the structure may be provided in containers, coated or not. The container material may be either hard or soft, and as will be appreciated by those skilled in the art, typically comprises a tasteless, easily administered and water-soluble compound such as gelatin, starch or a cellulosic material. In some embodiments, when the article comprises the container, then the reservoir, capsule, magnetic component, and / or tether may comprise the first configuration such that they are contained within the container. In some embodiments, when the article comprises the container, then the reservoir, magnetic component, and tether may comprise the first configuration such that they are contained within the container. In some embodiments, when the article comprises the container, then the capsule, magnetic component, and tether may comprise the first configuration such that they are contained within the container. For example, the tether may be bend, folded, compressed, or otherwise positioned to take up the minimal space when the article is in the first configuration within the container. The above-referenced ranges of the largest dimension of the article correspond to when the article is in a first configuration. In some embodiments, following ingestion of the article comprising the container, the container may be configured to degrade and / or dissolve to release the remaining components of the article at the location internal to the subject. In some embodiments, following release from the container, the remaining components of the article assume a second configuration, for example, as shown in FIG. 1A, wherein the components are no longer configured (e.g., compressed) to minimize the space in which they reside. In some embodiments, the largest dimension of the article in the second configuration is larger the largest dimension of the article in the first configuration. Some aspects are related to systems. In some embodiments, systems for delivering therapeutic agents to a subject are described. In some embodiments, gastric sensing systems are described. In some embodiments, systems for gastric sensing and for delivering therapeutic agents to a subject are described. In some embodiments, the systems comprise a plurality of articles, wherein the articles are as described elsewhere herein. In some embodiments, a system may comprise 2 articles, 3 articles, 4 articles, 5 articles, or 6 articles. In some embodiments, the system may comprise greater than or equal to 2 articles, greater than or equal to 3 articles, greater than or equal to 4 articles, greater than or equal to 5 articles, greater than or equal to 6 articles, greater than or equal to 7 articles, greater than or equal to 8 articles, greater than or equal to 9 articles, greater than or equal to 10 articles, greater than or equal to 15 articles, greater than or equal to 20 articles, or greater than or equal to 25 articles. In some embodiments, the system may comprise less than or equal to 30 articles, less than or equal to 25 articles, less than or equal to 20 articles, less than or equal to 15 articles, less than or equal to 10 articles, less than or equal to 9 articles, less than or equal to 8 articles, less than or equal to 7 articles, less than or equal to 6 articles, less than or equal to 5 articles, less than or equal to 4 articles, or less than or equal to 3 articles. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 2 articles and less than or equal to 10 articles). Other ranges are also possible. In some embodiments, the number and configuration of the article may be selected based on the desired system configuration. For example, note that the number of articles in the system, in some embodiments, is based on the desired amount of therapeutic agent present within the system and / or by the desired of the therapeutic agent from the system. As an example, FIG. 1D shows system 150 comprising a plurality of articles comprising magnetic components 120 operably linked (e.g., stacked and coupled by a magnetic force) together, each of which is connected to a reservoir 110 by a tether 130. Alternatively, in some embodiments, the number of articles may be selected based on the number of articles needed to contain certain combinations of sensors and other electronic components to facilitate gastric sensing. In some embodiments, the number of articles of the system is determined by the desired amount of therapeutic payload and the combination of sensors and other electronic components needed for certain gastric sensing configurations. Still other embodiments are possible, as this disclosure is not so limited. According to some embodiments, in the systems comprising multiple articles, each magnetic component of each article may be configured to self-assemble at the location internal to the subject. For example, the subject may ingest multiple articles over a period of time, for example, less than or equal to 5 minutes. In some embodiments, multiple articles may be administered (e.g., orally, endoscopically) substantially simultaneously (e.g., within 1 hour, within 30 minutes, within 10 minutes, and / or within 5 minutes). In some embodiments, one or more articles may be administered at a later time, e.g., after at least 1 hour, at least 1 day, at least 1 week, and / or up to 1 year. Following ingestion of the multiple articles, the magnetic components of the articles may self-assemble into a system at the location internal to the subject, in some embodiments. In some embodiments, self-assembly may comprise the magnetic components operably linking. Self-assembly may comprise stacking of the magnetic components, in some embodiments. For example, a first magnetic component of a first article may operably link to a second magnetic component of a second article to form a stack of the first and second magnetic components, thereby making a system comprising the first and second articles. Similarly, in some embodiments, a plurality of articles comprising 3 articles, 4 articles, and so forth, may operably link to form a system. Forming systems comprising multiple articles may be advantageous for a number of reasons. For instance, in some embodiments, a system comprising multiple articles may facilitate the retention of larger payloads of therapeutic agents within the reservoirs of each of the articles and long-term delivery of the payload of therapeutic agent to the subject. In some embodiments, systems comprising multiple articles include various electronic components that are in electronic and / or wireless communication with each other. In some such embodiments, the multiple articles advantageously provide additional sensors and / or electronic components that can communicate. Still other embodiments including multiple articles have one or more reservoirs for delivering a therapeutic agent and one or more capsules for gastric sensing. For instance, in some emvodiments, a system comprises two or more capsules; at least one capsule comprising one or more electronic components, at least one capsule comprising a power source in electronic communication with the one or more electronic components; a magnetic component; a tether operably linking the magnetic component to at least one of the two or more capsules; a reservoir configured to receive a therapeutic agent; and a second tether operably linking the reservoir and the magnetic component, where the system is configured for extended residence at a location internal to a subject. The formation (e.g., self-assembly) of the system comprising multiple articles may yield a system that is larger than the individual articles. In some embodiments, the system may be sized and adapted such that the system may not exit from the location internal to the subject, for example, from the stomach via the pylorus of the subject. Accordingly, in some such embodiments, the system may be retained at the location internal to the subject for an extended period of time. As mentioned above, in some embodiments, the system may have a maximum cross-sectional dimension that is on the order of and / or is larger than an exit from the subject, for example, the pylorus of the stomach. In some embodiments, the maximum cross-sectional dimension of the system may be less than or equal to 40 millimeters, less than or equal to 30 millimeters, less than or equal to 20 millimeters, less than or equal to 15 millimeters, or less than or equal to 10 millimeters. According to some embodiments, the maximum cross-sectional dimension of the system may be greater than or equal to 5 millimeters, greater than or equal to 10 millimeters, greater than or equal to 15 millimeters, greater than or equal to 20 millimeters, or greater than or equal to 30 millimeters. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 10 millimeters and less than or equal to 30 millimeters). Other ranges are also possible. Accordingly, in some embodiments, the articles are small enough to be ingested by the subject, where after the self-assembly of multiple articles yields a system that is too large to exit the subject. In some embodiments, the article, after release from the capsule, may assume a second configuration as described elsewhere here in that may be configured such that the article does not exit from the subject. In some embodiments, a plurality of articles and a second configuration may self-assemble to connect system that is sized and adapted to prevent passage from the subject, as described elsewhere herein. For example, in some embodiments, the tether of the article may extend when the article assumes its second configuration upon release from the capsule. Thus, in some embodiments, the size of the system may prevent it from passing and / or exiting the subject. In some embodiments, the system may be configurated to prevent passage and / or exiting from the subject. The system may be retained in the subject, in accordance with some embodiments, over the course of a relatively long time (e.g., a residence time). In some embodiments, the system is configured for extended residence at a location internal to the subject. For example, when articles self-assemble to form a system in the stomach of a subject, the residence time of the system may be relatively long in the stomach compared to typically ingested items, for example, food. In some embodiments, the system may be retained at the location internal to the subject for greater than or equal to 1 hour, greater than or equal to 10 hours, greater than or equal to 1 day, greater than or equal to 10 days, greater than or equal to 30 days, greater than or equal to 60 days, greater than or equal to 90 days, greater than or equal to 120 days, greater than or equal to 240 days, or greater than or equal to 300 days. According to some embodiments, the system may be retained at the location internal to the subject for less than or equal to 365 days, less than or equal to 300 days, less than or equal to 240 days, less than or equal to 120, less than or equal to 90 days, less than or equal to 60 days, less than or equal to 30 days, less than or equal to 10 days, less than or equal to 1 day, or less than or equal to 10 hours. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 1 hour and less than or equal to 365 days, greater than or equal to 10 days and less than or equal to 90 days). Other ranges are also possible. Additionally, because each article comprises at least one reservoir, the system comprising multiple articles comprises multiple reservoirs. The system comprising multiple reservoirs may facilitate the safe delivery of relatively large payloads of therapeutic agent, in some embodiments. As described elsewhere herein, each article may be configured to slowly release the therapeutic agent from the reservoir at the location internal to the subject. In some such embodiments, having a relatively large payload of therapeutic agent may facilitate the long-term delivery of the therapeutic agent at the location internal to the subject by using the system and may obviate the need for a subject to adhere to a treatment comprising a pill regimen as prescribed by a medical professional. The payload of therapeutic agent contained by the system, in some embodiments, is relatively large (e.g., as compared to traditional ingestible drug delivery systems). In some embodiments, the payload of therapeutic agent contained by the system is greater than or equal to 1 gram, greater than or equal to 2 grams, greater than or equal to 3 grams, greater than or equal to 5 grams, greater than or equal to 7 grams, greater than or equal to 9 grams, greater than or equal to 12 grams, greater than or equal to 15 grams, greater than or equal to 20 grams, greater than or equal to 25 grams, greater than equal to 30 grams, greater than or equal to 35 grams, greater than or equal to 40 grams, greater than or equal to 45 grams, greater than or equal to 50 grams, or greater than or equal to 75 grams of therapeutic agent. In some embodiments, the payload of therapeutic agent contained by the system is less than or equal to 100 grams, less than or equal to 75 grams, less than or equal to 50 grams, less than or equal to 45 grams, less than or equal to 40 grams, less than or equal to 35 grams, less than or equal to 30 grams, less than or equal to 25 grams, less than or equal to 20 grams, less than or equal to 15 grams, less than or equal to 12 grams, less than or equal to 9 grams, less than or equal to 7 grams, less than or equal to 5 grams, less than or equal to 3 grams, less than or equal to 2 grams of therapeutic agent. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 1 gram and less than or equal to 100 grams, greater than or equal to 3 grams and less than or equal to 50 grams). Other ranges are also possible. Note that the above ranges are in relation to the total capacity of the reservoirs of the system, in accordance with some embodiments. Accordingly, in some embodiments, each of the reservoirs may contain a smaller amount than those of the total system (e.g., comprising multiple reservoirs and / or articles), for example, less than or equal to 10 grams, less than or equal to 8 grams, less than or equal to 5 grams, less than or equal to 3 grams, less than or equal to 2 grams, less than or equal to 1 gram, less than or equal to 0.8 grams, less than or equal to 0.6 grams, less than or equal to 0.4 grams, less than or equal to 0.2 grams, less than or equal to 0.1 gram, or less than or equal to 0.05 grams of therapeutic agent. In some embodiments, each of the reservoirs may contain greater than or equal to 0.01 grams, greater than or equal to 0.05 grams, greater than or equal to 0.1 grams, greater than or equal to 0.2 grams, greater than or equal to 0.4 grams, greater than or equal to 0.6 grams, greater than or equal to 0.8 grams, greater than or equal to 1 gram, greater than or equal to 2 grams, greater than or equal to 3 grams, greater than or equal to 5 grams, or greater than or equal to 8 grams of therapeutic agent. Combinations of the foregoing ranges are possible. Other ranges are also possible. In some embodiments, as described elsewhere herein, multiple therapeutic agents may be present in one or more reservoirs of an article or system. For example, in some embodiments, each reservoir may comprise one or more different types and / or different concentrations of therapeutic agents. In some embodiments, a first reservoir may comprise a first therapeutic agent and a second reservoir may comprise a second therapeutic agent, the first therapeutic agent and second therapeutic agent being of different type and / or concentration. In some such embodiments, the foregoing ranges may describe the cumulative amount of the multiple therapeutic agents present. In other such embodiments, the foregoing ranges may describe the amount of the each of the therapeutic agents present. In other such embodiments, the foregoing ranges describe the cumulative amount of a single type of a therapeutic agent. As described elsewhere herein, patients may traditionally be prescribed a regimen of pills to take over the course of relatively long times, for example 30 days, 60 days, and so forth. Adherence to such regimens is often lacking by patients, which may lead to suboptimal treatments. Therefore, the relatively large payloads of therapeutic agent, in some embodiments, achieved in the systems described herein advantageously facilitate the relatively slow release of the therapeutic agent over a course of treatment and may obviate the need for the patient to take a pill daily. Without wishing to be bound by theory, the slow release of the therapeutic agent from the reservoirs of the articles of this system may occur by mass transport (e.g., diffusion) through the micro-outlet(s) present in each of the reservoirs, in accordance with some embodiments. According to some embodiments, as described in more detail elsewhere herein, the therapeutic agent may be loaded in a polymeric component, or a polymeric component may be present between the payload of the therapeutic agent in the reservoir and the micro-outlet, which may further regulate the release of the therapeutic agent from the reservoir when the article is at a location internal to the subject. In some embodiments, the release rate of the therapeutic agent from each of the reservoirs may be dependent on any of a number of factors, including the solubility of the therapeutic agent at the location internal to the subject, the diffusion coefficient of the therapeutic agent, the collective cross-sectional area of the one or more micro-outlets present in the reservoir, the average distance between the therapeutic agent present in the reservoir and a micro-outlet of the reservoir (e.g., associated with the length of the reservoir and the number of micro-outlets), and / or the presence of a polymeric component in which the therapeutic may be loaded. In some embodiments, the therapeutic agent is configured to be released from the reservoir in at a zero-order release rate. In some embodiments, the therapeutic agent is configured to be released from the reservoir in at a first-order release rate. In some embodiments, the therapeutic agent is configured to be released from the reservoir as a pulsatile release rate. In some embodiments, an actuation mechanism may be used to modulate a release rate of the therapeutic agent. For instance, in some embodiments, an actuation mechanism comprising a spring may apply a relatively constant force to a therapeutic agent such that it exits a micro-outlet at a constant rate for zero-order release. In some embodiments, one or more electronic components may provide feedback to an actuation mechanism to facilitate pulsatile release of a therapeutic agent from a reservoir. In some embodiments, the therapeutic agent is released at a slow rate, for example, compared to the total payload of therapeutic agent present in the article and / or system. According to some embodiments, the therapeutic agent is released from the system at a rate of greater than or equal to 0.0001 grams per day, greater than or equal to 0.0005 grams per day, greater than or equal to 0.001 grams per day, greater than or equal to 0.005 grams per day, greater than or equal to 0.01 grams per day, greater than or equal to 0.05 grams per day, greater than or equal to 0.1 grams per day, greater than or equal to 0.5 grams per day, greater than or equal to 1 gram per day, or greater than or equal to 1.5 grams per day. In some embodiments, the therapeutic agent is released from the system at a rate of less than or equal to 2 grams per day, less than or equal to 1.5 grams per day, less than or equal to 1 gram per day, less than or equal to 0.5 grams per day, less than or equal to 0.1 grams per day, less than or equal to 0.05 grams per day, less than or equal to 0.01 grams per day, less than or equal to 0.005 grams per day, less than or equal to 0.001 grams per day, or less than or equal to 0.0005 grams per day. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 0.0001 grams per day and less than or equal to 2 grams per day). Other ranges are also possible. In some embodiments, the therapeutic agent is contained within a triggerable drug release reservoir. For instance, in some embodiments, a reservoir contains a mechanism for modulating a release rate of the therapeutic agent from the reservoir. In some embodiments, the mechanism comprises an osmotic agent, a spring, and / or a pulsatile drug release mechanism. In some embodiments, the therapeutic agent is contained in a first portion of the interior volume of the reservoir and the mechanism is contained in a second portion of the interior volume that is separated from the first portion by a separator. In some such embodiments, when the mechanism comprises an osmotic agent or a spring, the mechanism may expand over time as the therapeutic agent is released from the reservoir via the micro-outlet as described above, applying a force to the separator. This force may alter the dimensions of the first portion and the second portion of the interior volume such that the release rate of the therapeutic agent from the reservoir changes. In this manner, in some embodiments, the release rate of the therapeutic agent is relatively constant (varying by no more than 50%, no more than 40%, no more than 30%, no more than 20%, no more than 10%, no more than 5%, or no more than 1% from an initial release rate). In some embodiments, when the mechanism is a pulsatile drug release mechanism, the mechanism may be configured to move a separator at different rates over time to modulate the release rate of the therapeutic agent from the reservoir. Some aspects are related to kits comprising the articles described herein. In some embodiments, the kits comprise a plurality of articles. In some embodiments, each of the plurality of articles in the kit does not contain a therapeutic agent, and may be configured such that a therapeutic agent may be loaded into each of the plurality of articles in the kit. In some embodiments, each of the plurality of articles may configured to be ingested by a subject. In some embodiments, some or all the plurality of articles are configured to contain a therapeutic agent. In some embodiments, some or all of the plurality of articles are configured for gastric sensing. In some embodiments, each of the plurality of articles may contain a therapeutic agent such that each of the plurality of articles is configured to be ingested by a subject. In some such embodiments, the kits may be configured to provide the number of articles recommended by a medical professional for a treatment requiring the therapeutic agent contained within the articles of the kit. Still, in some embodiments, a relatively large number of articles may be present in the kit such that the medical professional may receive the kit and may use the articles therein to provide treatment for any of a number of patients (e.g., greater than or equal to 1 patient, greater than or equal to 2 patients, greater than or equal to 5 patients, greater than or equal to 10 patients, and so forth). The plurality of articles contained in the kit may comprise greater than or equal to 2 articles, greater than or equal to 10 articles, greater than or equal to 50 articles, greater than or equal to 100 articles, greater than or equal to 200 articles, greater than or equal to 300 articles, greater than or equal to 500 articles, or greater than or equal to 750 articles. In some embodiments, the plurality of articles contained in the kit may comprise less than or equal to 1000 articles, less than or equal to 750 articles, less than or equal to 500 articles, less than or equal to 300 articles, less than or equal to 200 articles, less than or equal to 100 articles, less than or equal to 50 articles, or less than or equal to 10 articles. Combinations of the foregoing ranges are possible (greater than or equal to 10 articles and less than or equal to 100 articles). Other ranges are also possible. In certain embodiments, the reservoir contains one or more specific therapeutic agents. In some embodiments, greater than or equal to 2, greater than or equal to 3, greater than or equal to 4, greater than or equal to 5, greater than or equal to 6, greater than or equal to 7, greater than or equal to 8, or greater than or equal to 9 therapeutic agents are contained within a reservoir. In some embodiments, less than or equal to 10, less than or equal to 9, less than or equal to 8, less than or equal to 7, less than or equal to 6, less than or equal to 5, less than or equal to 4, less than or equal to 3 therapeutic agents may be contained within a reservoir. Combinations of the foregoing ranges are possible (e.g., greater than or equal to 2 and less than or equal to 10 therapeutic agents). Other ranges are also possible. In some embodiments, wherein multiple reservoirs are present, multiple different therapeutic agents may be present in some or all of the reservoirs. In some embodiments, wherein multiple reservoirs are present, different therapeutic agents (or the same therapeutic agent at different concentrations) may be present in different reservoirs. The presence of multiple therapeutic agents, in accordance with some embodiments, may facilitate the long-term delivery of synergistic therapeutic agents, for example, a first therapeutic agent providing a therapeutic effect and a second therapeutic agent mitigating side effects of the first therapeutic agent. In some embodiments, multiple therapeutic agents may be delivered concomitantly by a single reservoir for the long-term delivery of each therapeutic agent for different therapeutic effects. In some embodiments, a kit comprises at least two articles for delivering a therapeutic agent to a location internal to a subject, wherein each of the articles comprises: a reservoir; a magnetic component; and a tether operably linking the reservoir and the magnetic component, wherein each of the articles is sized and adapted for ingestion such that the article resides at the location internal to the subject. In some embodiments, a kit, comprises at least two articles for gastric sensing, wherein each of the articles comprises: a capsule containing an electronic component and / or a power source; a magnetic component; and a tether operably linking the reservoir and the magnetic component, wherein each of the articles is sized and adapted for ingestion such that the article resides at a location internal to a subject. In some embodiments, a kit comprises a first article for delivering a therapeutic agent to a location internal to a subject, comprising: a reservoir; a magnetic component; and a tether operably linking the reservoir and the magnetic component; and a second article for gastric sensing, comprising: a capsule containing an electronic component and / or a power source; a magnetic component; and a tether operably linking the reservoir and the magnetic component, wherein each of the articles is sized and adapted for ingestion such that the article resides at a location internal to a subject. As used herein, the term “therapeutic agent” or also referred to as a “drug” refers to an agent that is administered to a subject to treat a disease, disorder, or other clinically recognized condition, or for prophylactic purposes, and has a clinically significant effect on the body of the subject to treat and / or prevent the disease, disorder, or condition. Listings of examples of known therapeutic agents can be found, for example, in the United States Pharmacopeia (USP), Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th Ed., McGraw Hill, 2001; Katzung, B. (ed.) Basic and Clinical Pharmacology, McGraw-Hill / Appleton & Lange; 8th edition (September 21, 2000); Physician’s Desk Reference (Thomson Publishing), and / or The Merck Manual of Diagnosis and Therapy, 17th ed. (1999), or the 18th ed (2006) following its publication, Mark H. Beers and Robert Berkow (eds.), Merck Publishing Group, or, in the case of animals, The Merck Veterinary Manual, 9th ed., Kahn, C.A. (ed.), Merck Publishing Group, 2005; and “Approved Drug Products with Therapeutic Equivalence and Evaluations," published by the United States Food and Drug Administration (F.D.A.) (the “Orange Book"). Examples of drugs approved for human use are listed by the FDA under 21 C.F.R. §§ 330.5, 331 through 361, and 440 through 460, incorporated herein by reference; drugs for veterinary use are listed by the FDA under 21 C.F.R. §§ 500 through 589, incorporated herein by reference. In certain embodiments, the therapeutic agent is a small molecule. Exemplary classes of therapeutic agents include, but are not limited to, analgesics, anti-analgesics, anti-inflammatory drugs, antipyretics, antidepressants, antiepileptics, antipsychotic agents, neuroprotective agents, anti-proliferatives, such as anti-cancer agents, antihistamines, antimigraine drugs, hormones, prostaglandins, antimicrobials (including antibiotics, antifungals, antivirals, antiparasitics), antimuscarinics, anxiolytics, bacteriostatics, immunosuppressant agents, sedatives, hypnotics, antipsychotics, bronchodilators, anti-asthma drugs, cardiovascular drugs, anesthetics, anti–coagulants, inhibitors of an enzyme, steroidal agents, steroidal or non– steroidal anti–inflammatory agents, corticosteroids, dopaminergics, electrolytes, gastro- intestinal drugs, muscle relaxants, nutritional agents, vitamins, parasympathomimetics, stimulants, anorectics and anti-narcoleptics. Nutraceuticals can also be incorporated into the drug delivery device. These may be vitamins, supplements such as calcium or biotin, or natural ingredients such as plant extracts or phytohormones. In some embodiments, the therapeutic agent is one or more antimalarial drugs. Exemplary antimalarial drugs include quinine, lumefantrine, chloroquine, amodiaquine, pyrimethamine, proguanil, chlorproguanil-dapsone, sulfonamides such as sulfadoxine and sulfamethoxypyridazine, mefloquine, atovaquone, primaquine, halofantrine, doxycycline, clindamycin, artemisinin and artemisinin derivatives. In some embodiments, the antimalarial drug is artemisinin or a derivative thereof. Exemplary artemisinin derivatives include artemether, dihydroartemisinin, arteether and artesunate. In certain embodiments, the artemisinin derivative is artesunate. In another embodiment, the therapeutic agent is an immunosuppressive agent. Exemplary immunosuppressive agents include glucocorticoids, cytostatics (such as alkylating agents, antimetabolites, and cytotoxic antibodies), antibodies (such as those directed against T-cell receptors or Il-2 receptors), drugs acting on immunophilins (such as cyclosporine, tacrolimus, and sirolimus) and other drugs (such as interferons, opioids, TNF binding proteins, mycophenolate, and other small molecules such as fingolimod). In certain embodiments, the therapeutic agent is a hormone or derivative thereof. Non-limiting examples of hormones include insulin, growth hormone (e.g., human growth hormone), vasopressin, melatonin, thyroxine, thyrotropin-releasing hormone, glycoprotein hormones (e.g., luteinizing hormone, follicle-stimulating hormone, thyroid- stimulating hormone), eicosanoids, estrogen, progestin, testosterone, estradiol, cortisol, adrenaline, and other steroids. In some embodiments, the therapeutic agent is a small molecule drug having molecular weight less than about 2500 Daltons, less than about 2000 Daltons, less than about 1500 Daltons, less than about 1000 Daltons, less than about 750 Daltons, less than about 500 Daltons, less or than about 400 Daltons. In some cases, the therapeutic agent is a small molecule drug having molecular weight between 200 Daltons and 400 Daltons, between 400 Daltons and 1000 Daltons, or between 500 Daltons and 2500 Daltons. In some embodiments, the therapeutic agent is selected from the group consisting of active pharmaceutical agents such as insulin, nucleic acids, peptides, bacteriophage, DNA, mRNA, human growth hormone, monoclonal antibodies, adalimumab, epinephrine, GLP-1 Receptor agonists, semaglutide, liraglutide, dulaglutide, exenatide, factor VIII, small molecule drugs, progestin, vaccines, subunit vaccines, recombinant vaccines, polysaccharide vaccines, and conjugate vaccines, toxoid vaccines, influenza vaccine, shingles vaccine, prevnar pneumonia vaccine, MMR vaccine, tetanus vaccine, hepatitis vaccine, HIV vaccine Ad4-env Clade C, HIV vaccine Ad4-mGag, DNA vaccines, RNA vaccines, etanercept, infliximab, filgrastim, glatiramer acetate, rituximab, bevacizumab, any molecule encapsulated in a nanoparticle, epinephrine, lysozyme, glucose-6-phosphate dehydrogenase, other enzymes, certolizumab pegol, ustekinumab, ixekizumab, golimumab, brodalumab, guselkuab, secikinumab, omalizumab, tnf-alpha inhibitors, interleukin inhibitors, vedolizumab, octreotide, teriperatide, crispr cas9, insulin glargine, insulin detemir, insulin lispro, insulin aspart, human insulin, antisense oligonucleotides, and ondansetron. In other embodiments, the therapeutic agent is a protein or other biological macromolecule. In some embodiments, the therapeutic agent comprises isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), ethambutol (EMB), and / or Sofosbuvir, and accordingly may be suitable for treating Hepatitis C and / or tuberculosis. In some embodiments, the therapeutic agent comprises an analgesic such as oxycodone suitable for treating chronic pain of a cancer patient. In some embodiments, the therapeutic agent comprises an antibiotic such as amoxicillin and / or doxycycline which may be suitable for treating Lyme disease. In some embodiments, the therapeutic agent comprises an anticoagulant such as aspirin and / or Plavix which may be suitable in the setting of new stents or graft, either before and / or after the respective setting. In some embodiments, the therapeutic agent comprises an antidepressant. Non- limiting examples of suitable antidepressants include Citalopram (Celexa), Escitalopram (Lexapro), Fluoxetine (Prozac), Paroxetine (Paxil), Sertraline (Zoloft). In some embodiments, the therapeutic agent comprises an antidiabetic, e.g., metformin, Sitagliptin [Dpp-4], Empagliflozin [SGLT2]. In some embodiments, the therapeutic agent comprises an antiepileptic such as oxcarbazepine and / or Keppra. In some embodiments, the therapeutic agent comprises an antipsychotic such as risperidone (Risperdal), quetiapine (Seroquel), and / or olanzapine (Zyprexa). In some embodiments, the therapeutic agent comprises an antispasmodic and / or a neuropathic, e.g., baclofen and / or gabapentin. In some embodiments, the therapeutic agent comprises ACE Inhibitors, Angiotensin II Receptor Blockers, Angiotensin Receptor- Neprilysin Inhibitors, Beta Blockers, Calcium Channel Blockers, which may be suitable for treating cardiovascular-related diseases such as atrial fibrillation and / or tachycardia. In some embodiments, the therapeutic agent may be suitable for treating psychiatric-related issues, e.g., addition and / or other diseases such as schizophrenia. In some such embodiments, wherein the therapeutic agent is suitable for treating addition, the therapeutic agent may comprise nicotine, methadone, disulfiram, naltrexone, and / or Buprenorphine. In some embodiments, wherein the therapeutic agent is suitable for treating schizophrenia, the therapeutic agent may comprise quetiapine and / or risperidone. In some embodiments, each article (e.g., when one or more, two or more, three or more, etc. articles are administered to a subject) comprises the same or different therapeutic agent(s). In some embodiments, the therapeutic agent is one or more antimalarial drugs. Exemplary antimalarial drugs include quinine, lumefantrine, chloroquine, amodiaquine, pyrimethamine, proguanil, chlorproguanil-dapsone, sulfonamides such as sulfadoxine and sulfamethoxypyridazine, mefloquine, atovaquone, primaquine, halofantrine, doxycycline, clindamycin, artemisinin and artemisinin derivatives. In some embodiments, the antimalarial drug is artemisinin or a derivative thereof. Exemplary artemisinin derivatives include artemether, dihydroartemisinin, arteether and artesunate. In certain embodiments, the artemisinin derivative is artesunate. Therapeutic agents that contain a carboxylic acid group may be directly incorporated into polymeric matrices (e.g., present within a reservoir) that contain ester and hydroxyl groups without further modification. Therapeutic agents containing an alcohol may first be derivatized as a succinic or fumaric acid monoester and then incorporated into the polymeric matrix. Therapeutic agents that contain a thiol may be incorporated into olefin or acetylene-containing matrices through a sulfur-ene reaction. In other embodiments, the one or more therapeutic agents are non-covalently associated with the polymeric matrices (e.g., dispersed or encapsulated within). In other embodiments, the therapeutic agent is a protein or other biological macromolecule. Such substances may be covalently bound to the polymeric matrix through ester bonds using available carboxylate containing amino acids, or may be incorporated into polymeric material containing olefinic or acetylenic moieties using a thiol-ene type reaction. In some cases, the therapeutic agent comprises an amine functional group capable of reacting with an epoxide functional group to form an amide or ester bond. In other embodiments, the therapeutic agent is non-covalently associated with the polymeric matrix. In some such embodiments, the therapeutic agent may be dispersed or encapsulated within by hydrophilic and / or hydrophobic forces. In some cases, the partition coefficient of the therapeutic agent in the loadable polymeric component material can be tuned. For example, if the therapeutic agent is hydrophobic, a hydrophobic polymeric material backbone may, in some cases, slow the release into aqueous solution, however, a hydrophilic polymeric material backbone should accelerate it. Additionally, a hydrophilic polymeric material backbone may, in some cases, increase the rate of water absorption into the material, expanding (e.g., swelling) the polymeric material and accelerating release rate. The expansion and dissolution of the material may be increased, in some embodiments, under conditions when free reactive groups contain ionizable moieties that become charged in the presence of aqueous media. In some such embodiments, as the material disintegrates due to ionic repulsion, the rate of release of contents may be increased via diffusion and / or better access to cleavable bonds may be imparted. Those skilled in the art would be capable of selecting suitable methods for determining the partition coefficient of the therapeutic agent including, for example, high performance liquid chromatography (HPLC). The therapeutic agent may be associated with the polymeric matrix and / or present in the loadable polymeric component in any suitable amount. In some embodiments, the therapeutic agent is present in the loadable polymeric component an amount ranging between about 0.01 wt% and about 50 wt% versus the total loadable polymeric component weight. In some embodiments, the therapeutic agent is present in the loadable polymeric component in an amount of at least about 0.01 wt%, at least about 0.05 wt%, at least about 0.1 wt%, at least about 0.5 wt%, at least about 1 wt%, at least about 2 wt%, at least about 3 wt%, at least about 5 wt%, at least about 10 wt%, at least about 20 wt%, at least about 30 wt%, at least about 40 wt% of the total loadable polymeric component weight. In certain embodiments, the therapeutic agent is present in the loadable polymeric component in an amount of less than or equal to about 50 wt%, less than or equal to about 40 wt%, less than or equal to about 30 wt%, less than or equal to about 20 wt%, less than or equal to about 10 wt%, less than or equal to about 5 wt%, less than or equal to about 3 wt%, less than or equal to about 2 wt%, less than or equal to about 1 wt%, less than or equal to about 0.5 wt%, less than or equal to about 0.1 wt%, or less than or equal to about 0.05 wt%. Any and all closed ranges that have endpoints within any of the above-referenced ranges are also possible (e.g., between about 0.01 wt% and about 50 wt%). Other ranges are also possible. Advantageously, certain embodiments of the loadable polymeric components described herein may permit higher concentrations (weight percent) of therapeutic agents to be incorporated as compared to other polymers such as certain conventional hydrogels. In some embodiments, the therapeutic agent may be released from the loadable polymeric component. In certain embodiments, the therapeutic agent is released by diffusion out of the loadable polymeric component. In some embodiments, the therapeutic agent is released by degradation of the loadable polymeric component (e.g., biodegradation, enzymatic degradation, hydrolysis). In some embodiments, the therapeutic agent is released from the loadable polymeric component at a particular rate. Those skilled in the art would understand that the rate of release may be dependent, in some embodiments, on the solubility of the therapeutic agent in the medium in which the loadable polymeric component is exposed, such as a physiological fluid such as gastric fluid. The ranges and description included related to the release and / or rate of release of the active substance is generally in reference to hydrophilic, hydrophobic, and / or lipophilic active substances in simulated gastric fluid (e.g., as defined in the United States Pharmacopeia (USP)). Simulated gastric fluids are known in the art and those skilled in the art would be capable of selecting suitable simulated gastric fluids based on the teachings of this specification. In some embodiments, between 0.05 wt% to 99 wt% of the therapeutic agent initially contained in a loadable polymeric component is released (e.g., in vivo at a location internal to the subject) between 24 hours and 1 year. In some embodiments, between about 0.05 wt% and about 99.0 wt% of the therapeutic agent is released (e.g., in vivo at a location internal to the subject) from the loadable polymeric component after a certain amount of time. In some embodiments, at least about 0.05 wt%, at least about 0.1 wt%, at least about 0.5 wt%, at least about 1 wt%, at least about 5 wt%, at least about 10 wt%, at least about 20 wt%, at least about 50 wt%, at least about 75 wt%, at least about 90 wt%, at least about 95 wt%, or at least about 98 wt% of the therapeutic agent associated with the loadable polymeric component is released from the component (e.g., in vivo at a location internal to the subject) within about 24 hours, within 36 hours, within 72 hours, within 96 hours, or within 192 hours. In certain embodiments, at least about 0.05 wt%, at least about 0.1 wt%, at least about 0.5 wt%, at least about 1 wt%, at least about 5 wt%, at least about 10 wt%, at least about 20 wt%, at least about 50 wt%, at least about 75 wt%, at least about 90 wt%, at least about 95 wt%, or at least about 98 wt% of the therapeutic agent associated with the polymeric component is released from the component (e.g., in vivo) within 1 day, within 5 days, within 30 days, within 60 days, within 120 days, or within 365 days. For example, in some cases, at least about 90 wt% of the therapeutic agent associated with the polymeric component is released from the component (e.g., in vivo) within 120 days. In some embodiments, the therapeutic agent is released from the reservoirs of the system material at a particular initial average rate as determined over the first 24 hours of release (the “initial rate”) (e.g., release of the therapeutic agent at the location internal to the subject, such as an internal cavity). In certain embodiments, the therapeutic agent is released at an average rate of at least about 1%, at least about 2%, at least about 5%, least about 10%, at least about 20%, at least about 30%, least about 50%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, or at least about 98% of the initial average rate over a 24 hour period after the first 24 hours of release. In some embodiments, the therapeutic agent is released at an average rate of less than or equal to about 99%, less than or equal to about 98%, less than or equal to about 95%, less than or equal to about 90%, less than or equal to about 80%, less than or equal to about 75%, less than or equal to about 50%, less than or equal to about 40%, less than or equal to about 30%, less than or equal to about 20%, less than or equal to about 10%, less than or equal to about 5%, or less than or equal to about 2% of the initial average rate over a 24 hour period after the first 24 hours of release. Any and all closed ranges that have endpoints within any of the above referenced ranges are also possible (e.g., between about 1% and about 99%, between about 1% and about 98%, between about 2% and about 95%, between about 10% and about 30%, between about 20% and about 50%, between about 30% and about 80%, between about 50% and about 99%). Other ranges are also possible. The therapeutic agent may be released at an average rate over at least one selected continuous 24 hour period at a rate of between about 1% and about 99% of the initial rate between 48 hours and about 1 year (e.g., between 48 hours and 1 week, between 3 days and 1 month, between 1 week and 1 month, between 1 month and 6 months, between 3 months and 1 year) after the initial release. For example, in some cases, the active substance may be released at a rate of between about 1% and about 99% of the initial rate on the second day of release, the third day of release, the fourth day of release, the fifth day of release, the sixth day of release, and / or the seventh day of release. In certain embodiments, burst release of a therapeutic agent from the reservoir is generally avoided. In an illustrative embodiment, in which at least about 0.05 wt% of the active substance is released from the reservoir within 24 hours, between about 0.05 wt% and about 99 wt% is released during the first day of release (e.g., at the location internal to the subject), and between about 0.05 wt% and about 99 wt% is released during the second day of release. Those skilled in the art would understand that the active substance may be further released in similar amounts during a third day, a fourth day, a fifth day, etc. depending on the properties of the reservoir(s) and / or the therapeutic agent. The therapeutic agent may be released at a relatively constant average rate (e.g., a substantially zero-order average release rate) over a time period of at least about 24 hours (e.g., or over greater than or equal 10 days, 30 days, 60 days, and so forth as described elsewhere herein). In certain embodiments, the active substance is released at a first- order release rate (e.g., the rate of release of the active substance is generally proportional to the concentration of the active substance) of a time period of at least about 24 hours. In some embodiments, at least a portion of the therapeutic agent loaded into the reservoir is released continuously (e.g., at constant rates, at varying rates) over the residence time period of the system. Residence time periods are described in more detail elsewhere herein. Some aspects are related to methods, for example, of administering and / or using the articles described herein. In some embodiments, methods of administering a therapeutic agent to a subject are described. In some embodiments, the method comprises administering at least two articles to the subject such that the two articles self- assemble at a location internal to the subject to form a drug delivery system. In some embodiments, the article (and / or system) is administered to a subject (e.g., orally). In certain embodiments, the system may be administered orally, rectally, vaginally, nasally, endoscopically, and / or uretherally. In certain embodiments, upon reaching a location internal to the subject (e.g., the gastrointestinal tract), two or more articles self-assemble as described herein. In some embodiments, the location internally of the subject is the colon, the duodenum, the ileum, the jejunum, the stomach, or the esophagus. As described above and herein, in some embodiments, an active pharmaceutical ingredient may be released upon the article(s) reaching the location internal to the subject. By way of example, and without wishing to be limited by such an exemplary set of embodiments, the article(s) may be administered to a subject orally where, in some cases, the article(s) travels to the stomach of the subject, sinks to the bottom of the subject’s stomach, and the system self-assembles. In some embodiments, administering articles to a subject comprises internalizing the article. In some embodiments, administering articles comprises ingesting the articles by the subject. Administering a plurality of articles to a subject, in some embodiments, may comprise the subject internalizing (e.g., ingesting) each of the plurality of articles in a sequence. In some such embodiments, each of the plurality of articles is ingested over the course of a relatively short time, for example, less than or equal to 1 hour, less than or equal to 30 minutes, less than or equal to 20 minutes, less than or equal to 10 minutes, or less than or equal to 5 minutes, such that each of the plurality of articles may be located at the same location internal to the subject. According to some embodiments, asked described elsewhere herein, each of the articles of the plurality of articles may be contained within a capsule when ingested. In some embodiments, the capsule may facilitate the ingesting of the article. In some embodiments, when the articles are ingested while within a capsule, the remaining components of the article may be present in a first configuration so as to fit within the capsule. Accordingly, in some embodiments, following ingestion, the remaining components of each of the articles may be released from the capsules of each article and achieve the second configuration, for example, after the capsule degrades and / or dissolves upon encountering conditions internal to the subject. In some embodiments, the second configuration may be such that the tether of each of the articles may be at least partially extended, for example, as shown in FIG. 1A. The method comprises articles assembling into a drug delivery system at the location internal to the subject, in some embodiments. The method may further comprise articles self-assembling into a drug delivery system at the location internal to the subject, in some embodiments. For instance, following ingestion of the one or more articles by the subject, the articles may self-assemble at the location internal to the subject. Self- assembly may proceed by the magnetic component of each of the ingested articles associating together (e.g., through magnetic force) to form a stack of the magnetic components of each article, in some embodiments. Due to the reservoirs of each article being linked to the magnetic components of each article through their respective tethers, the self-assembly of the stack of magnetic components results in the drug delivery system comprising the plurality of articles, in some embodiments, e.g., as shown in FIG. 1D. In accordance with some embodiments, while the articles may self-assemble into the system, a magnet external to the subject may localize some or all of the articles to a single location internal to the subject such that self-assembly may occur more rapidly than in the absence of the external magnet. In some embodiments, assembly of the articles is facilitated by a magnet external of the subject. In some embodiments, assembly of the articles is facilitated by a magnetic field generated external to the subject (e.g., via a magnet, via an induction coil). Accordingly, in some embodiments, the method comprises applying an magnetic field such that the two or more articles assemble into a system. In some embodiments, one or more of the magnetic components of the articles of this system may comprise a resistor. In some embodiments, the method further comprises measuring the impedance and / or resistance across the resistor of the magnetic component. The measurement from the resistor may be wirelessly transmitted from the location internal to the subject to the receiver external to the subject. Wireless transmission of the data, in some embodiments, may be achieved through the use of conventional microelectronics, and those of ordinary skill in the art will be able to select the appropriate microelectronics to facilitate the transmission of the data collected from the resistor of the system. Without wishing to be bound by theory, the impedance measured across the resistor generally varies as a function of the number of magnetic components associated with the initial magnetic component containing the resistor, as each magnetic component may further comprise a resistor and thus the impedance of the system generally increases as a function of the number of magnetic components. Accordingly, in some embodiments, the self-assembly of the plurality of articles into the drug delivery system can be monitored externally by monitoring the data transmitted from the resistor. According to some embodiments, as described elsewhere herein, the drug delivery system comprising multiple articles may be sized and / or adapted such that it may not pass and / or exit from the location internal of the subject. For instance, in some embodiments, the system is sized and / or adapted so that it may not exit through the pylorus from the stomach of the subject. In some embodiments, the method further comprises retaining the drug delivery system at the location internal to the subject for greater than or equal to 1 hour, greater than or equal to 1 day, greater than or equal to 30 days, and so forth as described elsewhere herein. In some embodiments, wherein the system is adapted so that it may not exit through the pylorus, at least a portion of the system may begin to exit through the pylorus without entirely passing through (e.g., a reservoir of an article may pass through the pylorus). In some such embodiments, partial passing of the system through the pylorus is not desirable. Thus, in some embodiments, the method may further comprise repositioning the system in the location internal to the subject. Repositioning the system in the location internal to the subject, in some embodiments, may proceed by using a magnet that is external to the subject to manipulate the magnetic components of each article of the system while the system is internal to the subject. In this manner, in some embodiments, the system may be repositioned if the system assumes a position within the subject that is undesirable. In some embodiments, the method further comprises releasing the therapeutic agent from the drug delivery system over a period of time. In some embodiments, after the drug delivery system self assembles at the location internal to the subject from the plurality of articles ingested by the subject, the drug delivery system may reside at the location internal to the subject for a period of time. During this period of time, in some embodiments, the drug delivery system may release the therapeutic agent from the reservoirs of each article of the drug delivery system at rates disclosed elsewhere herein (e.g., greater than or equal to 0.0001 grams per day and less than or equal to 2 grams per day). In some embodiments, releasing of the therapeutic agent from their reservoirs may proceed through a micro-outlet, as described elsewhere here in. The release of the therapeutic agent from the drug delivery system may proceed for at least a portion (e.g., greater than or equal to 5%, greater than or equal to 10%, greater than or equal to 25%, greater than or equal to 50%, greater than or equal to 75%, up to 90% of the time) and up to the entire time that the drug delivery system resides at the location internal to the subject. In some embodiments, releasing therapeutic agent from the drug delivery system at the location internal to the subject is a form of treatment for the subject. The method may further comprise disassembling the system at the location internal the subject, in some embodiments. Disassembling the system at the location internal to the subject, in some embodiments, may be desirable after a therapeutic dose of the therapeutic treatment has been received by the subject. In some embodiments, the system may be disassembled at the location internal to the subject because the subject receiving the therapeutic agent from the system may have an adverse reaction to the therapeutic agent, e.g., after ingestion of the articles comprising the system. In some embodiments, as described elsewhere herein, the tether or a degradable linker of the reservoir or magnetic component of the articles of the drug delivery system may be degradable, for example, under conditions present at the location internal to the subject. In some embodiments, degradation of the tether (e.g., a degradable tether) and / or degradable linker of the reservoir of the articles may proceed when the articles of the system are present at the location internal of the subject and may result in the system disassembling as the tethers of at least one of the articles of the system degrade. Disassembling the system via degradation of the tethers or degradable linker of the articles of the system may occur over relatively long time, in some embodiments, in line with the desired amount of time for the system to be at the location internal of the subject. For instance, complete degradation of at least one tether or degradable linker of an article of the system (e.g., such that the tether no longer links the reservoir to the magnetic component) may occur, in some embodiments, over the course of greater than or equal to 10 days, greater than or equal to 30 days, greater than or equal to 60 days, or so forth as described elsewhere herein for the residence time of the system. In some embodiments, disassembly of the system may be triggered external to the subject. For example, as described elsewhere herein, in some embodiments, the articles may comprise an actuation mechanism. In some embodiments, an actuation mechanism may be administered toa subject at a separate time from administration of one or more articles, where the administration of the actuation mechanism is configured to disassemble the system. In some embodiments, the actuation mechanism may be actuated to disassemble the system when the system is present at the location internal to the subject. In some embodiments, wherein the actuation mechanism comprises of spring, the spring may be compressed until the actuation mechanism is initiated. Once initiated, the spring may decompress and facilitate the disassembly the system, in some embodiments. Accordingly, in some embodiments, methods may comprise triggering disassembly of a system, e.g., via an actuation mechanism. In some embodiments, the actuation mechanism may be present within a reservoir or capsule (e.g., within an interior volume defined by the reservoir or capsule) and administered at a time after the article and / or system is present at a location internal to the subject.. In some embodiments, the actuation mechanism may be present within a reservoir or capsule (e.g., within an interior volume defined by the reservoir or capsule) of an article of the system. In some embodiments, the actuation mechanism comprises a spring and a liquid configured to disassemble the system. Accordingly, in some embodiments, upon actuation of the actuation mechanism, the liquid is released from the reservoir or capsule of the article comprising the actuation mechanism and the liquid may disassemble the system, e.g., by reacting with at least a portion of the system. In some embodiments, reacting with at least a portion of the system may comprise reacting with the tethers and / or other components of the system, for example, a washer present where the tether connects with the reservoir and / or magnetic component of each article of the system. For example, in some embodiments, the actuation mechanism may comprise ethylenediaminetetraacetic acid (EDTA), glutathione (GSH), calcium chloride, and / or eutectic gallium indium (EGaIn) and / or be configured to release the same from the interior of a reservoir. In some such embodiments, one or more components (e.g., a tether, magnetic components, a degradable linker, etc.) may be configured to react with any of the foregoing actuation mechanisms, for example, the one or more components may comprise aluminum, polyvinyl alcohol, polyacrylamide, and / or alginate. Those of ordinary skill in the art will be able to select suitable, biocompatible materials for various aspects of the articles and / or systems which are further reactive with certain components of actuation mechanism (e.g., EDTA, EGaIn, etc.). Whether disassembling the system occurs through the degradation of at least one component of an article of the system or through an actuation mechanism, disassembling the system may facilitate, in some embodiments, the release (e.g., exit) of the articles of the system from the location internal to the subject. In some embodiments, the system may comprise a degradable portion (e.g., a tether, a linker) and an actuation mechanism, such that disassembly of the system may occur on a long timeline in line with the degradation of the degradable portion of may be actively initiated by the actuation mechanism. EXAMPLES The following examples are intended to illustrate certain embodiments of the present invention, but do not exemplify the full scope of the invention. EXAMPLE 1 This example describes the development of an ingestible stackable capsule system (e.g., a stack of ingestible articles, a system comprising articles) capable of delivering multigram drug doses over an extended period. One of the most persistent challenges in clinical medicine is that of medication adherence. In this Example, an orally ingestible, stackable capsule (ISC) system with the potential to revolutionize medication adherence across a wide range of diseases / disorders is described. Utilizing this multigram drug depot platform, substantial amounts of antibiotics—6 grams of doxycycline and 27 grams of isoniazid— were successfully loaded, and were utilized to show a pharmacological relevant release in preclinical swine models over the course of several weeks. In addition, the ISC system’s feasibility as a long-term monitoring platform is demonstrated by integrating a microphone and temperature sensor. Beyond adherence and / or compliance, such an approach has the potential to affect patient convenience and quality of life and may also drastically impact a significant number of outstanding challenges in global health. Introduction Oral drug delivery holds a prominent position in health care and clinical medicine due to several inherent advantages over alternative routes. These include safety, convenience, rapid administration, and overall patient comfort. However, ensuring long- term patient compliance and adherence to complex oral medication regimens remains a significant clinical challenge due to various factors, such as the need for appointment scheduling, understanding dosage frequency, and / or the coordination of medication refills. Unsurprisingly, failure to adhere to a prescribed therapy can lead to serious medical and economic consequences. Less than 50% of patients with chronic conditions in developed countries adhere to their treatment recommendations or medication regimens. Adherence rates are even worse in low- and middle-income countries (LMICs). In response to this complex challenge, several innovative approaches have been put considered, including targeted behavioral and educational interventions, integrated patient care models, specialized drug packaging, and patient reminders. Nonetheless, successful implementation of such methodologies remains challenging, resulting in suboptimal outcomes. Consequently, there has been a renewed interest in the development of next generation gastric resident systems (GRS). These systems minimize the need for frequent drug administration, thereby improving patient adherence via a non-invasive route. The allure of GRSs lies in their capacity to reside in the stomach, thereby facilitating sustained drug release over extended periods. For instance, numerous GRSs have been developed which allow for mechanical integrity during gastric residency and sustained release of various drugs over the course of several weeks. However, most ingestible GRSs have a limited drug depot capacity, supporting only 10–30% of the device’s volume. This limitation principally arises from the substantial volume occupied by the residency components. As a result, these systems are unsuitable for addressing a wide range of health disorders that require gram-level dosing. Alternative designs to typical devices often present alternative challenges, e.g., requiring nasogastric implantation and / or endoscopic removal thereby, limiting their adoption and usability. In this Example, an orally ingestible stackable capsule (ISC) system is developed. This technology can facilitate multi-gram dosing over an extended period(s), making it an effective treatment option for a wide range of diseases and disorders. The ISC system is designed for one-time oral administration and assembles rapidly in the stomach (i.e., < one minute); its unique aggregating shape allows for long-term retention in the stomach. Notably, the system utilizes greater than 90% of the total system volume for the loaded drug and in so doing can accommodate multi-gram levels. Given the inherent modularity engineered into the ISC system, the number of capsules can also be tailored to meet patient needs and long-term dosing / treatment regimens. Critically, to mitigate risks related to potentially overdosing, a durable drug encapsulation subsystem has been designed (referred to as the containers in this Example, but will be understood to be the reservoirs of the systems described herein) that remains stable for several weeks within the gastric environment. Finally, the need for a retrieval procedure is eliminated by including a disassembly subsystem, allowing the ISC system to be safely excreted. From a safety perspective, each system component, once disassembled, is smaller than the FDA-approved osmotic-controlled release oral delivery system (OROS, outer diameter of 9 mm and a length of 15 mm), which is known to be safe for transit within the gastrointestinal tract. To assess the potential clinical applications of the ISC system, in vivo retention and pharmacokinetic (PK) studies were conducted using swine models. In these studies, the ISC system was deployed to study treatment regimens that would require dosing at the gram level for several weeks. The initial focus was on antibiotics, such as doxycycline and isoniazid, because these drugs are effective in treating and preventing bacterial and parasitic infections so long as strict adherence is maintained to avoid antibiotic resistance and opportunistic infections. Six grams of doxycycline and 27 grams of isoniazid were loaded into the ISC system and confirmed to sustain drug release, at relevant therapeutic levels, in swine models over 6 weeks and 8 weeks, respectively. Beyond antibiotics, the potential of the ISC system was demonstrated using naltrexone, a drug commonly employed to manage opioid use disorders. Additionally, the feasibility of the ISC system as a long-term monitoring platform was demonstrated, which was shown by integrating a robust power supply, such as battery, a microphone, and temperature sensor. These data highlight the clinical potential of the ISC system to serve as a versatile platform for long-term treatment and complex regimens that require gram-level drug administration, alongside long-term continuous monitoring. Results ISC design The ISC system is designed for one-time oral administration and can deliver gram-level doses of medication over a period of several weeks. This innovative platform system obviates the need for multiple tablets, positioning it to ultimately improve medication adherence (FIG. 2A). As illustrated in FIG. 2B, each individual subcomponent of the ISC system is composed of two polycaprolactone (PCL) containers, which contain the drug and a magnet holder designed to facilitate self-assembly. Each container has a diameter of 9 mm and a height of 13 mm, allowing for drug loading at the gram-level and long-term control of drug release through micro-outlets. The magnet holder at the center has a diameter of 7 mm and a height of 1.5 mm. The holder and two containers are connected by a suture. To prevent oxidation issues, the magnet is coated with parylene and completely isolated with a cover . For ease of administration, the dosage form is packaged in a standard 000-size gelatin capsule, which rapidly dissolves upon reaching the stomach. The capsules as described in this Example should be understood to be the containers as described elsewhere herein. Degradable linkers and triggerable elements have also been incorporated between the suture and the container, and between the magnet holder and the suture, respectively, to facilitate disassembly post-treatment. In this Example, the number of ISC systems that was used was based on the prescribed daily dosage of target medication over the duration of treatment. Thus, 5 ISC systems with a total of ~ 6 g of doxycycline and 20 ISCs with ~ 27 g of isoniazid targeting a daily dose of 100 and 300 mg, respectively, were loaded over a 6 to 8-week treatment period (FIG. 2C and FIGS. 3A-3D). ISC system and operation An overview of the ISC system is provided in FIG. 2D. Briefly: (1) given the composite nature of the system, sequential ingestion of more than 3 ISC dosage forms is required for gastric retention; each of these holds two containers and a magnet holder, which is connected by a suture: (2) for ease of administration, the dosage form is contained within a 000-gelatin capsule, which is rapidly dissolved upon reaching the acidic environment within the stomach; (3) after ingestion, the deployed ISC systems are immediately attracted to each other by the magnet holder; (4) as a result, the ISC system forms a composite geometry with an effective diameter larger than the pylorus (~2 cm), which results in gastric retention; (5) notably, a safe methodology was established that facilitates real-time verification of the number of attached devices via an embedded electrical system. Consequently, clinical end-users can monitor stacking events in real time, thereby eliminating the need for x-ray verification and / or other imaging-based methods whilst ensuring magnet safety. This renders the system accessible for deployment in regions lacking access to advanced medical facilities at the time of ingestion. (6) the drug is ultimately released in a pre-programmed manner; and (7) because each capsule is embedded with both a biodegradable linker and a triggerable element, it can be disassembled at a pre-programmed time or an on-demand, triggerable manner. After disassembly, all component parts of the ISC system are safely excreted without evidence of obstruction / perforations etc. In vitro performance tests To demonstrate the versatility of the ISC system, doxycycline and isoniazid were selected, both of which are used in the prophylaxis and / or treatment of malaria and tuberculosis, respectively. Beyond antibiotics, the capacity of the ISC system to deliver naltrexone (a small molecule drug used in opioid and alcohol addiction management) was also assessed. A 5-ISC based system was engineered and loaded with approximately 6 g of doxycycline for an equivalent daily dose of 100 mg, a 20-ISC based system and loaded with approximately 27 g of isoniazid for an equivalent daily dose of 300 mg, and 3-ISC based system to load approximately 4.5 g of naltrexone for an equivalent daily dose of 50 mg. The studies were conducted over 60-, 90-, and 30-day periods, respectively. The ISC dosage forms are loaded per container with either 0.62 ± 0.02 g of doxycycline, 0.68 ± 0.03 g of isoniazid, or 0.8 ± 0.03 g of naltrexone. The in vitro release profiles was examined of each drug loaded within the containers equipped with a single micro-hole of varying cross-sectional area (FIG. 4A). The drug release process was initiated when water infiltrated the micro-hole, thereby dissolving the drug; the dissolved drug subsequently diffused through the same micro-hole. As depicted in FIGS. 4B-4D, a smaller micro-hole size led to prolonged drug release. By adjusting the cross-sectional area of the micro-holes, the release rate could be tuned in accordance with Fick’s law and the estimated diffusion flux. In so doing, release rates ranging from 0.79 % / day to 1.44 % / day over 41 days for doxycycline, 1.03 % / day over 81 days for isoniazid, and from 2.38 % / day to 3.03 % / day over 29 days for naltrexone were achieved, with percentages representing percent released vs. total drug loading within the container. In these studies, zero-order release (R2 > 0.98) for all groups was observed. To assess the stability of the test medications, a high-performance liquid chromatography (HPLC) analysis of the chemical properties of doxycycline, isoniazid, and naltrexone after release was conducted. Drug samples in simulated gastric fluid (SGF) with a pH of 2 to mimic stomach conditions and assayed them over a 30-day period were prepared. By comparing the HPLC-measured area values of samples from Day 0 with those at subsequent time points, it was found that the values were consistent, indicating that all drugs maintained their chemical properties for over several weeks (FIG. 5). Three tensile strength tests (i.e., between the drug container and suture, between the magnet holder and suture, and between magnet-magnet constructs) were also performed. These tests were conducted after immersing these components completely in SGF at 37 °C for 8 weeks (FIG. 4E). For each setup, a trend of decreasing rupture force over time was identified, which is likely due to degradation of material within the SGF. As shown in FIG. 4F, the forces of the magnet holder–suture and drug container–suture decreased from 5.6 ± 0.5 N to 4.6 ± 0.4 N and 5.8 ± 0.6 N to 4.7 ± 0.4 N, respectively, which is an ~ 30% decrease over the course of 4 weeks. In the 8th week, the rupture force of the drug container–suture degraded further by ~ 28% to around 3.34 ± 0.9 N, while the magnet holder–suture force remained stable at ~ 3.98 ± 0.5 N. The magnetic attraction force between two sets of NdFeB magnets (i.e., one with a diameter of 3 mm and a thickness of 1 mm, and the other with a diameter of 5 mm and a thickness of 1 mm) at 0, 4, and 8 weeks was also examined. The findings showed that when the magnets were displaced by 0 mm, they exerted a consistent force of 5.4 ± 0.2 N, 5.1 ± 0.1 N, and 5.0 ± 0.2 N for 5 mm–5 mm magnets and 3.1 ± 0.1 N, 3.0 ± 0.1 N, and 2.9 ± 0.2 N for 3 mm–3 mm magnets at each time point. Additionally, the magnetic forces of both tested magnetic systems were observed to approach zero when the distance between the magnets exceeded 5 mm (FIG. 4G). Finite element simulations Finite element analyses (FEA) were also employed to understand the mechanical interactions of the ISC system(s) with the pylorus and stomach. Specifically, a number of ISC system(s) were simulated under the influence of gravity that were directed into a 20 mm outlet funnel mimicking a pylorus. In the simulations, various ISC system designs with a number of stacks that ranged between 1, 2, 5 and 20, with suture lengths of 10, 15 and 20 mm were examined. FIG. 4H provides the Von-Mise stress distribution of a 1- stack ISC system with 20 mm length and a 5-stack ISC system with 20 mm length. Simulation results indicate that an ISC system with a stack number less than 2 tended to fall into and / or pass through the neck outlet of the funnel set-up with relative ease whilst the maximum stress concentration appears to happen within the suture as the ISC system interacts with the funnel. FIGS. 4I and 4J are heat maps which depict the maximum contact pressures and suture stresses of the different ISC systems when they fall freely into the funnel; the magnitude of the contact pressure of the ISC system touching the funnel is significantly smaller as compared with the suture pulling stress when the ISC system fell freely. Moreover, increasing the number of stacks (up to 5) did not significantly change the maximum contact pressure (FIG. 4I), which suggests that one can expect a similar mechanical performance of ISC systems inside the stomach. More than that, these simulations suggest that increasing the number of stacks to greater than 5 significantly increases the maximum pulling and tension stress of the ISC system when it jounces and falls inside a stomach, which could lead to unwanted early detachment of the drug container with the core magnetic components (FIG. 4J). Furthermore, tests were carried out to measure the force required for the transit of the ISC system through an in vitro funnel set-up, which simulated a pylorus with a 20 mm outlet. Forces of 1.5 N or more are ideal for maintaining the dosage form in the stomach. In this experiment, the suture length and the number of stacked devices was varied and as a result, it was found that sutures longer than 15 mm and stacks of more than 3 ISC systems did not pass through at less than 5 N (FIGS. 6A-6C). Wireless electronic subsystem In addition, a wireless electronic subsystem on the magnet holder to verify the ISC system stack assembly was incorporated. This electronic system detects the attachment of multiple ISC systems and transmits this information to a connected mobile device via Bluetooth Low Energy (BLE) using a radial-electrode parallel connection strategy (FIG. 4K). Each ISC magnet subassembly contains a 10 kΩ resistor (R1), which is electrically connected in parallel when the ISCs stack together (FIGS. 4L-4M). While a series connection would be easier to measure, it became evident that the stack measurement subsystem was required to work in any position of the stack. The stack resistance was measured using a standard voltage divider circuit (FIG. 7), and in so doing the number of connected ISC systems can be computed. The total resistance of the circuit decreases geometrically according to the equation, where 'n' represents the number of ISC systems in contact, and Ri Rparasitic. The value of 1kΩ per Rstackwas selected empirically after testing resistors of varying magnitudes and identifying a suitable engineering balance between stack detector power consumption and accuracy. As shown in FIG. 4N, an actual resistance profile was confirmed that is comparable to the expected resistance profile when 5 magnet holders were sequentially assembled whilst accounting for parasitic resistance effects secondary to the gastric environment. Long-term retention of ISC systems in swine models To demonstrate safe gastric retention and excretion in vivo, the ISC systems were deployed into the gastric cavity of Yorkshire pigs weighing between 60-80 kg. Yorkshire pigs have previously been employed as animal models for the evaluation of long-term drug delivery platforms given that their gastric anatomy is similar to that of human. The 3-, 5- and 20-ISC dosage forms were administered under anesthesia, via an endoscope and overtube, and rapidly formed aggregate shapes in the stomach (i.e., over the course of minutes) (FIG. 8A and FIG. 9). Subsequently, prolonged gastric retention of a 5-ISC system loaded with doxycycline and a 20-ISC system loaded with isoniazid were assessed by obtaining a series of radiographs over a span of 6 and 8 weeks, respectively (FIGS. 8B-8C and FIGS. 3A-3D). The magnet holder in both studies was also demonstrated to remain intact, in vivo, after attachment (FIG. 9B). Disassembly of ISC systems As mentioned above, the ISC system is equipped with a degradable linker (i.e., between the container and suture). This design allows the ISC system to be disassembled in a predictable manner (FIG. 8D). As shown in the representative image (FIG. 8E), disassembly was observed to begin on ~ day 38, and by day 48, all ISCs had been excreted. From a safety perspective, when necessary for patient care, the ISC system is also equipped with an on-demand disassembly feature, referred to as the intervention- triggered subsystem in this Example. The triggerable capsule was designed to be ingested for ease of use and as depicted in FIG. 8F, the dimensions are in fact compatible with insertion into a 000-gelatin capsule. As shown in FIG. 8G, the triggerable capsule consists of two major parts: an actuator with a sugar plug, loading chamber, septum and spring, and a container that has a gelatin film cap and an attachment magnet connected via a degradable suture, which allows the triggerable solution to be locally infused after attaching to the ISC system. The sugar plug is made entirely out of isomalt to be dissolved by gastric fluid within 10 min. The container has large gaps in the bottom that are capped by a 17.0 ± 2.5 µm gelatin film. This specific thickness of gelatin film allows it to dissolve at the same rate as the sugar plug (FIGS. 9C-9D). A degradable suture is attached to a magnet thread through a small hole in the bottom of the container. The container can then be filled with ~400 µl triggerable solution and the actuator can be secured to the top of the container. The eutectic gallium indium (EGaIn) serves as a triggerable solution and activates the aluminum washer designed as the triggerable element in the ISC system, as shown in figure 3H. These washers secure the sutures in place, holding the ISC system together. The triggerable capsule operates on a time delay actuation mechanism, as depicted in FIG. 8I. The process begins during the (1) ingestion phase, wherein the capsule is administered orally. Upon reaching the stomach, gastric fluids initiate the (2) attachment phase by dissolving the gelatin capsule, enabling rapid attachment of the triggerable capsule to the ISC systems. Exposure to the gastric environment causes the sugar plug and gelatin film to dissolve. Approximately 10 minutes later, both the sugar plug and gelatin film have dissolved, which unblocks the previously obstructed gaps in the container and allows for the compressed spring to extend. This propels the septum to the bottom of the container, facilitating the ejection of the triggerable solution. This marks the beginning of the (3) disassembly phase, during which the triggerable solution activates a chemical reaction within the ISC system. This reaction dissolves the fasteners that connect the major system components, allowing the ISC systems to break down into smaller elements initiating the (4) gastric emptying phase. Subsequently, the suture that is linked to the attachment magnet of the triggerable capsule undergoes degradation, allowing the components to disassemble and therefore pass safely through the pylorus. When EGaIn contacts the aluminum washers in the ISC system, it initiates a chemical reaction known as liquid metal embrittlement. At body temperature, EGaIn is in a liquid state, enabling it to flow between the grain boundaries of the solid aluminum fasteners. Over the course of approximately 10 minutes, this disrupts the cohesion between the grains of aluminum and significantly weakens the structural integrity of the fasteners. As a result, the aluminum becomes embrittled, losing its ability to withstand mechanical stresses. This embrittlement leads to the dissolution of the aluminum washers within the ISC systems, which allows for the sutures to separate from the magnet holder, separating the components into small components (FIG. 8J). In vivo pharmacokinetic profile An analysis was conducted of the oral pharmacokinetics of doxycycline in the swine model. As depicted in FIG. 10A, the plasma concentration of doxycycline in treated pigs revealed that the 100 mg doxycycline tablet was rapidly absorbed into the bloodstream, resulting in a peak plasma concentration of 507 ± 128 ng / ml (n = 3). In most pigs, the maximum concentration was attained at approximately 6 hours after administration. Following 24 hours of dosing, the mean concentration decreased to 81.8 % of the peak concentration (92.3 ± 61.9 ng / ml, n =3), and after 48 hours, the mean concentration declined to 98.8 %, reaching 6.25 ± 4.28 ng / ml (n = 3). In contrast, drug in plasma at therapeutically relevant concentrations was detected up to 48 days after administering a 5-ISC system, at which point the mean plasma concentration was 554 ± 275 ng / ml (n = 3) (FIGS. 10B-1C). For isoniazid, a similar PK study was conducted by delivering an ISC device containing approximately 27 g of isoniazid. During the course of this experiment, an average concentration of 101 ng / ml was maintained for over 8 weeks (FIG. 3D). In vivo safety testing In the pursuit of achieving long-term, gram-level dosing through one-time oral administration, the current ingestible system utilizes self-assembly via magnetism. In this system, each capsule rapidly attaches together, allowing for real-time confirmation of device attachment via the wireless resistor embedded within the magnet holder, observable from outside the body. Importantly, once these magnets attach, they maintain their integrity as a single metallic unit until the device exits from the body (FIGS. 3B and 9B). To ensure the safety of such an approach, an in vivo passage test was conducted using a single ISC system and a 5-stacked magnet holder connected with sutures (FIGS. 11A011B). To examine extreme scenarios that could arise due to the magnet’s integration in the intestine, safety passage tests were also conducted for the magnet; given that the magnet’s attractive force is crucially dependent on distance, we first verified the force between two magnets via tensile testing. It was found that when the distance between two magnets exceeds 5 mm, the force is virtually negligible. As such in vitro experiments were carried out to simulate a situation where multiple capsules pass through the pylorus just before deployment within the stomach. As shown in FIGS. 12A- 13D, it was confirmed that even if such a scenario occurs, the attractive force is virtually zero because the distance (i.e., tissue thickness) separating the magnets exceeds 5 mm. Furthermore, tests were conducted to simulate a case where two or more capsules pass through the pylorus before they attach to each other, following the oral ingestion of multiple capsules (FIGS. 6A-6C). Given that the magnet holder is suspended between two containers, this scenario also demonstrated no attachment issues in the in vitro passage tests (n=10, FIGS. 12A-13D). In line with such findings, even when three deployed capsules were deliberately guided through the pylorus in a swine model using an overtube and endoscope, all devices passed without any obstructive issues (n=3, FIG. 14). Given these data and that no issues related to the magnets were observed in the 15 pigs used for in vivo retention and PK studies, such an approach seems to have an acceptable safety profile. Further, despite the prolonged presence of these aggregated ISC systems within the stomach, the mucosal surfaces of the test animals’ stomachs remained intact, without gross signs of injury, erosions, or ulcerations. Moreover, there was no evidence of gastrointestinal obstruction(s) or any evidence to suggest perturbations or pathology in the lower GI tract. Notably, the weight of animals in both groups (i.e., the 5-ISC and a 20-ISC systems) was comparable to the control group (FIGS. 3D and 10C). eISC system for long-term monitoring Given the remarkable capacity of the ISC system, it can simultaneously accommodate a diverse array of sensors and batteries, which are crucial for a long-term monitoring platform. Among the key applications are temperature measurement and cardiac activity monitoring, both of which are integral for comprehensive body monitoring. Continuous tracking of body temperature is invaluable, as it serves as a primary indicator for potential infections, offering higher precision when measured internally compared to external methods. Similarly, persistent cardiac activity monitoring is essential for early detection of cardiovascular conditions, facilitating targeted preventive measures or optimized therapeutic interventions. In response to these critical needs, an electronic ISC (eISC) has been developed for long-term monitoring (FIGS. 15A-15F). This component, which is part of the stackable magnetic gastric resident system, can monitor temperature, recording audio data via an integrated microphone, and transmitting the collected data via Bluetooth. It is also optimized for battery efficiency, thereby supporting prolonged measurements periods. A schematic representation of the complete temperature and microphone sensor system, including interfacing with the computer or smartphone, is provided in FIG. 16. As depicted in FIG. 15B, the polypropylene chassis houses critical components including batteries and a flexible printed circuit board (PCB) equipped with a temperature sensor and a microphone. This flexible PCB is not integral not only for capturing temperature readings and detecting acoustic signals but also for transmitting this data via Bluetooth communication. Detailed design specifications of the flexible PCB are provided in the FIGS. 17A-17C. The choice of a flexible PCB over a rigid alternative is driven by its capacity to maintain functionality under bending conditions, thereby enhancing spatial efficiency within constrained environments, which is essential for facilitating ease of ingestion. The microcontroller seamlessly integrates the temperature sensor and Bluetooth low energy (BLE) communication, with the microphone interfaced through a non-inverting operational amplifier (op-amp) circuit. The selection of acoustic data for cardiac activity representation was made due to its independence from specialized interface or continuous tissue contact, unlike electrocardiography (ECG) or photoplethysmography (PPG), while still delivering adequate accuracy. Initially, long-term in vitro evaluations were conducted to validate the performance of the proposed temperature monitoring components. The data presented in FIG. 18 demonstrate that the device remained functional for 19 days at a temperature of 34.5 ± 0.75 °C, which approximates the ambient conditions within the testing chamber. Subsequently, in vivo tests were conducted to monitor both internal temperature and cardiac activity within the stomach of a swine model, thereby confirming the eISC's capability to continuously record and transmit data. Representative images in FIGS. 15D and 15E illustrate the eISC affixed to the remainder of the ISC system. The results shown in FIG. 15F indicate that the eISC effectively measures and transmits the core temperature of the subject without any disruptions. Notably, following the eISC’s deployment in the swine model, an initial spike in temperature was observed, which subsequently stabilized at the model’s internal temperature of 37.8 ± 0.6° C. For cardiovascular monitoring, 10 minutes of activity was recorded, segmented into 5-minute intervals before and after subject termination. These recordings were then compared with simultaneously acquired ECG data. The profiles shown in FIG. 15G (large panel) exhibit a close correspondence and similar response patterns, although the microphone measurements exhibited elevated noise level due to external disturbances and circuit interference. Within both profiles (FIG. 15G, small panel), distinct pulse features, such as the QRS complex, T, U, and P wave, were identifiable allowing for the detection of cardiovascular conditions that may alter these characteristics. By analyzing the R-peak time differences and estimating the heart rate from both measurements, the eISC’s accuracy was validated in monitoring the subjects’ cardiac conditions. Discussion Adherence to prescribed therapeutic protocols / medication regimens is crucial for the effective clinical management of a broad range of health conditions. Nonetheless, challenges associated with high doses and extended courses of medications often result in treatment non-compliance and / or abject clinical failures. Recent advancements in oral drug depot systems have aimed to address these challenges by engineering systems capable of indwelling in the stomach for extended periods, thereby facilitating gram- level drug dosing for long-term therapies. While such approaches are promising, existing technologies face several critical limitations. For instance, the previously referenced coil-shaped drug delivery system can accommodate and large drug doses but requires invasive and uncomfortable delivery methods (e.g., nasogastric implantation) and ultimately necessitate further removal. Similarly, drinkable hydrogels and floating systems can also achieve gram-level drug dosing, but their relatively short gastric residency times restrict sustained drug release and may lead to premature drug dumping. To tackle such challenges, in this Example, the development and engineering of the first ingestible capsule that can deliver multi-gram doses over an extended period. Following one-time oral administration, each 000-sized capsule deploys an ISC unit that assembles within the stomach in minutes (FIG. 2). Importantly, each capsule is equipped with a wireless resistor attached to the magnet for external monitoring, thereby eliminating the need for x-ray imaging (FIG. 4). The resultant ISC cluster, with its unique configuration, does not pass through the pylorus, thus enabling long-term retention and continuous drug release in the stomach for several weeks. This innovative approach holds significant potential for enhancing medication adherence and improving patient outcomes. It is prudent to note that the ISC system possesses substantial volumetric capacity, accounting for over 90% of the device’s total volume. This unique feature allows the ISC system to hold a considerable amount of medication, making it suitable for a wide range of diseases and disorders by obviating the need for multiple oral administrations. Furthermore, the rate of drug release and treatment duration can be precisely controlled and titrated by adjusting the outlet dimension and the number of capsules (FIG. 4). Given its composite nature, the ISC system would also allow for the inclusion of multiple drugs and drug type, thereby allowing for the treatment of multiple and / or complex diseases and disorders. Each constituent within the ISC system was also meticulously designed to be more compact than the FDA-approved OROS and can be disassembled either in pre- programmed or “on demand” manner, thus eliminating the need for a retrieval procedure whilst concurrently minimizing the risk of gastrointestinal obstruction. The long-term in vitro testing and in vivo experiments demonstrate that the attraction force between two devices exposed to a gastric environment remains comparable to that of fresh devices (FIG. 4G). In addition, once deployed in the stomach, the devices do not separate and can be considered a single / composite entity (FIG. 9A). Despite this, in vitro and in vivo safety experiments were conducted to assess extreme scenarios, confirming the capsule’s safety (FIGS. 11A-13D). Following in vitro funnel tests and FEA modeling, we have verified that ISC systems comprising three or more capsules stacked can reside in vivo for over a month (FIGS. 3A-3D, 8A-8J, and 9B). The testing with a 5-ISC system containing doxycycline and a 20-ISC system containing isoniazid, each with drug regimens and delivery periods in mind, has demonstrated that they could maintain drug concentration well in a swine model for over 6 weeks and 8 weeks, respectively. Moreover, body weight comparison between the device and control groups showed no significant differences (FIGS. 10A- 10C). For effective clinical translation and implementation, several enhancements, including miniaturization, additional safety testing, and efficacy validation, will be necessary to refine the prototype ISC system. Ensuring adequate protection against potential rupture risks of the device is essential, and future iterations of ISC containers and magnet may incorporate biocompatible metals with high mechanical strength, such as stainless steel or titanium. Besides, while the ISC’s self-assembly capability is well-established, its functionality can be further enhanced through the integration of a wearable or portable external magnet-based system under the healthcare provider supervision. This would streamline and enhance the safety of ISC system assembly in the stomach. Particularly for patients requiring medication every 2-3 months, this system could significantly improve the feasibility and effectiveness of long-term oral drug delivery, analogous to routine visits to a pharmacy or clinic. Additionally, the ISC system shows great promise as a platform for both long- term physiological monitoring and electrical applications. This potential is particularity significant given that most ingestible electronics face inherent limitations, such as inadequate retention features the within the gastric environment and insufficient capacity for power and control circuitry. Future advancements could integrate a range of sensors for gastric oxygen, hydrogen sulfide, carbon dioxide, hydrogen, pH, and pressure . Additionally, these developments may facilitate the creation of closed-loop systems capable of real-time monitoring and drug delivery. In conclusion, in this Example, the development of an orally available multigram drug depot system (ISC) is presented. The clinical application of this ISC system would signify a transformative shift given its ability to serve as an oral platform for the extended release and delivery of large doses of medications. In particular, the ISC system has the potential to supplant existing oral medications that require gram-level dosing over extended periods, including those used to treat hepatitis C, cancer, leukemia, Lyme disease, depression, diabetes, psychosis, and epilepsy. In addition, the ISC system can be facilitated to deliver a combination of multiple drugs, including steroids, perioperative antibiotics, and antiepileptic drugs for postoperative brain tumors, or H. Pylori triple therapy. Methods ISC Fabrication Containers were designed using Fusion360 software (D’assault Systemes, Waltham, MA). The materials used to fabricate the containers consisted of a 50:50 w / w blend of polycaprolactone (PCL) (Perstorp CAPA 6400, Malmo, Sweden) and barium sulfate (Sigma Aldrich 243353). The constituents were melt-blended using a speed mixer model DAC 330-100 Pro (Flacktek Landrum, SC). Printed model “masters” with a casting sprue were then modeled into the geometry using a 3D printer (Formlabs, Somerville, MA) and clear resin with a 25-micron layer height. These masters were used to form negative silicone molds using Moldstar 31T silicone (Smooth On, Macungie, PA) and centrifuged them at 2500 rpm to remove bubbles. After curing, the masters were removed from the mold and inserted the PCL composite material, which was then melted and centrifuged at the same settings to produce copies of the original design. After cooling, the containers were removed and inserted them into a jig to facilitate cutting the sprue and adding perforations at defined positions in the side walls of the container. Lids were fabricated for the containers by punching 9 mm circles from a 1 mm thick sheet of the same composite material using a hydraulic press (Carver Wabash, IN). In this Example, doxycycline, isoniazid, and naltrexone pills were prepared using a Natoli pill press (NP-RD10A (Saint Charles, MO)). To obtain a homogeneous powder, each API was mixed with Polyethylene glycol (PEG) (BASF) and Magnesium stearate (Sigma) in a 98:1.5:0.5 (w / w ratio). The pills were prepared at a size of 8 mm in diameter and 12 mm in height. The drug pills and lids were inserted into containers by controlled melt- forming using a hot plate and laser-cut jig with an aluminum foil cover. After that, the containers were assembled using a nylon suture of size 0.4 mm (Ethicon) threaded through the perforations and securing the sides. The suture ends were retained in the containers by melt-forming a wide knot. The main measurement unit of the wireless sensor is connected to a resistor and the microcontroller, an Arduino Feather nRF52, through traces on a flexible PCB. To reduce current flow to the microcontroller, a 10 kΩ resistor (R2) is placed between the power supply and the positive lead. The power supply is a SiO-2 battery with a DC voltage of 3.1 V, providing a stable voltage to the sensing elements. The microcontroller serves as the data acquisition and transmission unit, using a 2.4 GHz Bluetooth transceiver. Uniaxial tensile testing For the in vitro validation of the ISC system components’ strength and corrosion stability, the connections between the magnet holder and the suture, the drug container and the suture, and the magnet-to-magnet strength were tested. For the experiments, ADMET tensile machine (eXpert 5952, ADMET, Inc., Norwood, MA, USA) with a load cell of 100 N attached was used. The test machine was equipped with pneumatic grips and smooth or knurled jaws. Neodymium magnets (NdFeB) were used and dimensioned at 5 mm diameter and 1 mm height. The suture used was monofilament Nylon suture (USP 1) and threaded through designated holes to the magnet holder and drug container and kept in place with biocompatible cyanoacrylate glue. In the case of magnet-to- magnet connection, they were glued to wooden skewers to be attached to the test machine. All the components for the corrosion testing were immersed in SGF (pH 2) at 37 °C for a total of 8 weeks. The testing of the drug container-suture connection involved securing two drug containers between smooth jaws to avoid suture damage. The grips were extended at a 10 mm / min load-displacement rate until component failure, and the failure tensile force was measured at 0 days, 30 days, and 60 days, with a sample size of 3. For the magnet holder-suture connection, the magnet holder was held between smooth jaws while the suture was held between knurled jaws to increase friction and prevent slippage. The experiment followed a similar procedure, measuring the failure tensile force at the same time intervals with a sample size of 3. In the case of the magnet- to-magnet connection strength, the magnets were connected, and the jaws held the skewers in place. The grips were extended at a 10 mm / min load-displacement rate, and the magnetic attractive force was measured using a sample size of 3. Funnel test To ensure that the ISC system would not pass from the pylorus, an in vitro customized funnel test setup was developed to simulate the stacked devices passing through the pylorus. A polypropylene funnel was used to simulate the pylorus, which has an upper diameter of 10 cm, a lower diameter of 2 cm, and a height of 10 cm. An Admet eXpert 5952 machine was utilized in conjunction with a custom rigid plunger to compress the stacked devices into the funnel, which was secured to the base of the machine with a custom jig to hold it in place. The plunger was programmed to push the stacked devices through the funnel at a rate of 1 mm / s, and the force and displacement were recorded. Numerical simulations Finite element analysis (FEA) was performed to understand the contacting performance of the ISC system with a funnel that simulates a pylorus. The dynamic explicit solver of the commercial FEA software Abaqus 2021 (SIMULIA, Providence, RI) was employed to simulate the ISC system falling freely into the funnel, under gravity. The funnel’s outlet was 20 mm to mimic the size of pylorus and the start position of ISC systems was set to be the center of the top plane of the funnel mouth. Suture lengths of 10 mm, 15 mm, and 20 mm, and ISC system stack numbers between 1, 2, 5, and 20 were considered in the simulation. The funnel is considered to be a rigid body to ease the computation cost of the simulation. Properties used to conduct the simulation are listed in Table 1. Hard normal contact and penalty tangential contact with a friction coefficient of 0.25 were considered as the contact model as the ISC system was falling into the funnel. In vitro performance test In vitro release profiles were investigated of doxycycline, isoniazid, and naltrexone in SGF at pH 2 and 37 °C. The release medium was continuously stirred at 50 rpm in a shaking incubator (INNOVA44, USA). Containers of each drug type were immersed in the release medium and collected aliquots at scheduled intervals for 60, 96, and 30 days, respectively. HPLC was then used to measure the amount of drug released in each sample. All experiments were performed in triplicate for each container type. To assess the drug stability of doxycycline, isoniazid, and naltrexone in SGF, each drug solution was prepared at a concentration of 0.2 mg / ml in a 37 °C incubator with 50 rpm rotation. At pre-determined time points, samples were collected and froze at -80 °C. Subsequently, the samples were analyzed using HPLC to compare retention time and area to that of Day 0 samples, examining their chemical stability. In vitro release studies were performed using an Agilent Technologies (Santa Clara, CA, USA) 1260 Infinity II HPLC, consisting of a binary pump, an autosampler, a temperature-controlled column compartment, and a UV-visible spectrum diode array detector (DAD). Doxycycline samples were injected at a volume of 20 µL and were separated on an Agilent Eclipse XDB C18 column (4.6 × 150 mm ID, 5 µm dp), with the column compartment temperature set to 45 °C. The mobile phase consisted of 0.1% formic acid in water (v / v) (A), and acetonitrile (B), pumped at a flow rate of 1.0 mL / min. The gradient elution program used was as follows: 0 min, 5% B; 10 min, 70% B; 13 min, 70% B; with a re-equilibration time of 3 min. Doxycycline was quantified by the DAD signal measuring absorbance at 293 nm at a bandwidth of 4 nm and data rate of 2.5 Hz. Isoniazid samples were injected at a volume of 5 µL onto an Agilent Eclipse XDB C18 column (4.6 × 150 mm, 3.5 µm dp), with TCC temperature set to 27 °C. The mobile phase consisted of 10 mM disodium phosphate adjusted to pH 6.75 with phosphoric acid (A), and acetonitrile (B), pumped at 1.2 mL / min with an isocratic composition of 4% B and 5 minutes between injections. UV absorbance was measured at 238 nm with a bandwidth of 4 nm and scan rate of 2.5 Hz. The LLOQ was determined to be 0.5 µg / mL. Naltrexone samples were injected at a volume of 2 µL onto an Agilent Poroshell EC-C18 column (3.0 × 50 mm, 2.7 µm dp), with temperature set to 50 °C. The mobile phase consisted of 0.1% formic acid in water (v / v, A), and acetonitrile (B), pumped at 1.0 mL / min, with a gradient program of 0 min, 5% B; 2.5 min, 45% B; 2.6 min, 95% B, with a runtime of 4 min and equilibration time of 1.5 min. UV absorbance was measured at 282 nm with a bandwidth of 4 nm and a scan rate of 10 Hz. The LLOQ was measured at 1 µg / mL. Triggerable capsules The triggerable capsules were designed using Fusion 360 software (D’assault Systemes, Waltham, MA). The 3D-printed materials used to assemble the capsules and actuator were 3D printed in black resin using a Form 3 (Formlabs, Somerville, MA) and in MED610 clear and RGD450 on an Objet260 Connex3 (Stratasys, Eden Prairie, MN). The isomalt pin was fabricated using a positive mold 3D printed in RGD450 (Stratasys, Eden Prairie, MN) and used to make a negative mold using silicone. Molten isomalt was then poured into this negative mold to make the isomalt pin. After that, the isomalt pin dissolution rate was tested by assembling the actuator and submerging them in SGF at 37 °C. A jig was also 3D printed in RGD450 on the Objet260 Connex3 to aid in loading the spring into the actuator. The loading chamber was placed into the jig, then the spring was placed on the septum, which were then both placed into the jig. The jig pushed the septum into the loading chamber, then the pin was placed into the top of the loading chamber, securing the septum and locking the spring. In the actuator, the spring diameter fits around the stems of the septum but is too wide to fit through the hole in the loading chamber. This allowed the septum stems to be pushed through the hole of the loading chamber while the spring gets compressed. Once the stems of the septum are through the hole in the loading chamber, the sugar plug was inserted through the top to push the stem tabs outwards, locking the actuator together. Approximately 400 µl of EGaIn was then filled into the capsule, and the actuator was placed into the top of the capsule and secured using a glue. For the capsule, the capsule and magnet holder were 3D printed in MED610 clear. A gelatin film was prepared by mixing 10% w / v gelatin and distilled water at 70 °C. Then, the film was fully immersed in a petri dish and allowed to dry out for 24 hours. This created a thin, plastic-like film that was then cut into small circles using a hole punch. This gelatin film was then glued to the bottom of the capsule using Vetbond glue (3M). Then, the gelatin film dissolution rate was tested after submerging it in SGF at 37 °C. A nylon suture was then threaded through the bottom of the capsule and gelatin film and secured by melting a bead at the tip of the suture inside the capsule. The suture was then threaded through the magnet holder, leaving about 1 cm of space between the magnet holder and the capsule, and the magnet was press-fit into the holder to secure the suture in place. In vivo evaluation test in pigs The animal experiments conducted in this Example were approved by the Committee on Animal Care at the Massachusetts Institute of Technology (protocol #:2207000395). female Yorkshire pigs (CBSET, Inc., Grafton, MA) weighing between 60-80 kg were fed twice daily with a diet of pellets and a midday snack of fruits and vegetables. Animals were fasted overnight before administration procedures to ensure safe anesthesia and to avoid aspiration. Pigs were sedated with Telazol (5mg / kg; tiletamine / zolazepam) and xylazine (2 mg / kg) or dexmedetomidine (0.03 mg / kg) and midazolam (0.25 mg / kg), intubated, and maintained on 1 to 3% isoflurane in oxygen and their vital signs were monitored. Blood samples were collected either through the insertion of a central venous catheter into the ear vein or via mammary bleed using a butterfly needle. The ISC system was administered through the overtube, with endoscopic visualization confirming their placement in the stomach. To assess the device's mechanical integrity and gastric residency, weekly X-rays were performed, and blood samples were collected for pharmacokinetic analysis. The blood was then centrifuged, and the plasma stored at -80°C. After the experiment, the pigs were administered atipamezole to reverse the effects of the dexmedetomidine and monitored until they were able to move around on their own. Liquid Chromatography Triple Quadrupole Mass Spectrometry (LQ-MS / MS) was used to determine model drug concentrations in all in vivo serum and plasma samples. An Agilent 1200 HPLC system with a binary pump, autosampler, and thermostat was coupled to a Thermo Scientific TSQ Quantiva triple quadrupole mass spectrometer. Data sets were generated using the Xcalibur® LC-MS control suite, and data processing and analysis were performed in TraceFinder®. Doxycycline (API) and oxytetracycline (ISTD) were separated on an Agilent Poroshell 120 EC-C18 analytical column of 3.0 x 50 mm with 2.7 µm particles and maintained at 45 °C. The optimized mobile phase consisted of A: 0.1% formic acid and 10 mM ammonium formate in water, and B: acetonitrile. Gradient elution was employed over 6 minutes, starting with 95% A at 0 min and ending with 5% A at 6 minutes at a flow rate of 0.5 mL / min. The injection volume was 5 µL. The compounds underwent electrospray ionization (positive mode) with an ion transfer tube temperature of 400 °C, vaporizer temperature of 450 °C, a sheath gas flow rate of 50 (arbitrary units), an auxiliary gas flow rate of 15 (arbitrary units), and a sweep gas flow rate of 1 (arbitrary units). The capillary voltage was set to 4500 V, and there was no in-source fragmentation. Doxycycline and oxytetracycline were monitored under SRM (selective reaction monitoring) with transitions of 445.2 m / z → 428.2 m / z and 461.2 m / z → 426.2 m / z for doxycycline and tetracycline, respectively. Q1 resolution was set to 0.7 Da, Q3 resolution was set to 0.7 Da, the CID gas was set to 1.5 mTorr, and the collision energies were set as 20 V for doxycycline and tetracycline, respectively. An LLOQ of 500 pg / mL was achieved using the sample preparatory and analytical methodologies conveyed in this report. Isoniazid and iproniazid (ISTD) samples were injected at a volume of 1 µL and separated on an Agilent Eclipse XDB C18 column (4.6 × 150 mm, 5 µm dp) held at 25 °C. The mobile phase consisted of 10 mM ammonium acetate in water (A) and acetonitrile (B), pumped at 1.000 mL / min with a gradient program of 0 min, 5% B; 5 min, 60% B; 5.1 min 90% B; 7 min, 90% B, and an equilibration time of 2 min. Mass spectra were acquired with an Agilent 6495A triple quadrupole mass spectrometer equipped with an Agilent JetStream electrospray ionization source. Source parameters were set to 230 °C drying gas temperature, 20 L / min drying gas flow, 45 psig nebulizer pressure, 400 °C sheath gas temperature, 12 L / min sheath gas flow, 2500 V at the capillary, and 0 V at the nozzle. The ion funnel RF voltages were set to 200 V at high pressure and 100 V at low pressure. Spectra were acquired in positive mode monitoring the 138.0 → 79.0 m / z (CE 37 V) transition to quantify isoniazid, with 138.0 → 121.0 m / z (CE 16 V) as a qualifying transition, and 180.0 → 138.0 m / z (CE 16 V) to quantify ISTD, with 180.0 → 121 m / z (CE 24 V) as a qualifying transition. Data were analyzed using MassHunter Quant Version 10.1. The LLOQ for the method was 1.0 ng / mL. eISC system for long-term monitoring A microcontroller (nRF52832, Nordic Semiconductor) was selected for its role in reading data from the temperature sensor and transmitting it via Bluetooth to an external device. This choice was influenced by the availability of a comprehensive development kit (nRF52 DK), a compatible mobile application (nRF Connect for mobile), and a current consumption measurement tool (Power Profiler Kit II (PPKII)). Additionally, this microcontroller’s integrated temperature sensing circuit, commonly referred to as a CMOS temperature sensing circuit, was a decisive factor in its selection. For antenna requirements, a ceramic Bluetooth antenna with a transmission frequency of 2.45MHz, surface-mount device (SMD) encapsulation, and dimensions of 3.2 x 1.6 mm (model ANT3216LL00R2400A) was chosen. To address spatial constraints in the design of the ingestible device and avoid obstructions, four SR626 batteries were selected for their compact diameter. Lastly, a flexible PCB was developed to house all these components. To evaluate the system’s functionality, an in vitro test was conducted. This involved using a calibrated and certified temperature logger with an accuracy of ±0.5°C and operational range of -20 to 40 ℃ to compare against the eISC. The certified logger was programmed to record temperature measurements every hour and store these values internally. Concurrently, the eISC was set to take hourly measurements and transmit data via Bluetooth to a computer. Both devices were initiated simultaneously and positioned side at a controlled temperature of approximately 35°C, 1.5 meters from the receiving computer. After approximately 19 days, our eISC ceased transmitting, indicating battery depletion. This was confirmed by measuring the internal batteries. Comparison of the data from the certified logger and the eISC transmission is depicted in figure S14. In parallel, current consumption measurements for the eISC were performed using the Power Profiler Kit II (PPKII). The PPKII was connected to the eISC, with its internal adjustable voltage source serving as the power supply. The eISC was programmed to transmit temperature data at a frequency of 5 seconds, the maximum allowed by the device. The PPKII was set to sample at a rate of 100,000 samples per second. The results, shown in FIGS. 19A-19B. indicate that the eISC’s current consumption is approximately 46.8uA. EXAMPLE 2 The Example describes gastric sensing articles having different time delayed monitoring systems. FIG. 20A shows a schematic illustration of a first system comprising six capsules at a location internal a subject, each capsule containing one or more sensors and a power source. Each capsule is further configured to wirelessly communicate with a master device, i.e., a smart phone external the subject. The device is configured such that a first capsule may measure a condition via a sensor until a power source of the first capsule is depleted, thereafter a second capsule is configured to do the same. Following depletion of the power source of the second capsule, a third capsule is then activated, and so forth until the sixth capsule is used. In this manner, long term monitoring is facilitated via the system. Similarly, FIG. 20B shows a schematic illustration of a first system comprising six capsules at a location internal a subject, each capsule containing one or more sensors and a power source. The system is configured with near-field communication (NFC) to communicate with a master smartphone external the subject. In this system, the capsules (i.e., slave devices) are configured to transmit data via the near field communication in an energy efficient manner for long term monitoring. In this instance, the system is configured to alternately acquire data at the first capsule, then the second capsule, third capsule, and so forth until recycling back to the first capsule. EXAMPLE 3 The Example describes drug release articles having different release rate kinetics. A first article was constructed as shown in FIG. 21A, where the article includes a reservoir 2100 containing an osmotic agent 2110 and a therapeutic agent 2120. As the therapeutic agent 2120 is released through an outlet 2130 of the reservoir 2100, the osmotic agent 2110 expands so that the therapeutic agent 2120 continues to release at a relatively constant rate 2140 (i.e., zero order release). A second article was constructed as shown in FIG. 21B, where the article includes a reservoir containing an osmotic agent microchannel containing a dissolvable polymer, a dissolvable isomalt pin, compressed springs, a drug (i.e., a therapeutic agent), and a teflon cap. In this arrangement, the article is configured such that the polymer dissolves, then the isomalt pin dissolves, and a first spring releases a first portion of the drug, followed by a second spring releasing a second portion of the drug, and so forth. This system facilitates a pulsatile release of the drug. While several embodiments of the present invention have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and / or structures for performing the functions and / or obtaining the results and / or one or more of the advantages described herein, and each of such variations and / or modifications is deemed to be within the scope of the present invention. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and / or configurations will depend upon the specific application or applications for which the teachings of the present invention is / are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, the invention may be practiced otherwise than as specifically described and claimed. The present invention is directed to each individual feature, system, article, material, and / or method described herein. In addition, any combination of two or more such features, systems, articles, materials, and / or methods, if such features, systems, articles, materials, and / or methods are not mutually inconsistent, is included within the scope of the present invention. The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.” The phrase “and / or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Other elements may optionally be present other than the elements specifically identified by the “and / or” clause, whether related or unrelated to those elements specifically identified unless clearly indicated to the contrary. Thus, as a non-limiting example, a reference to “A and / or B,” when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A without B (optionally including elements other than B); in another embodiment, to B without A (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc. As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and / or” as defined above. For example, when separating items in a list, “or” or “and / or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e. “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law. As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and / or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc. As used herein, “wt%” is an abbreviation of weight percentage. Any terms as used herein related to shape, orientation, alignment, and / or geometric relationship of or between, for example, one or more articles, compositions, structures, materials and / or subcomponents thereof and / or combinations thereof and / or any other tangible or intangible elements not listed above amenable to characterization by such terms, unless otherwise defined or indicated, shall be understood to not require absolute conformance to a mathematical definition of such term, but, rather, shall be understood to indicate conformance to the mathematical definition of such term to the extent possible for the subject matter so characterized as would be understood by one skilled in the art most closely related to such subject matter. Examples of such terms related to shape, orientation, and / or geometric relationship include, but are not limited to terms descriptive of: shape - such as, round, square, circular / circle, rectangular / rectangle, triangular / triangle, cylindrical / cylinder, elipitical / elipse, (n)polygonal / (n)polygon, etc.; angular orientation - such as perpendicular, orthogonal, parallel, vertical, horizontal, collinear, etc.; contour and / or trajectory – such as, plane / planar, coplanar, hemispherical, semi-hemispherical, line / linear, hyperbolic, parabolic, flat, curved, straight, arcuate, sinusoidal, tangent / tangential, etc.; surface and / or bulk material properties and / or spatial / temporal resolution and / or distribution – such as, smooth, reflective, transparent, clear, opaque, rigid, impermeable, uniform(ly), inert, non-wettable, insoluble, steady, invariant, constant, homogeneous, etc.; as well as many others that would be apparent to those skilled in the relevant arts. As one example, a fabricated article that would described herein as being “ square" would not require such article to have faces or sides that are perfectly planar or linear and that intersect at angles of exactly 90 degrees (indeed, such an article can only exist as a mathematical abstraction), but rather, the shape of such article should be interpreted as approximating a “ square," as defined mathematically, to an extent typically achievable and achieved for the recited fabrication technique as would be understood by those skilled in the art or as specifically described. Some embodiments may be embodied as a method, of which various examples have been described. The acts performed as part of the methods may be ordered in any suitable way. Accordingly, embodiments may be constructed in which acts are performed in an order different than illustrated, which may include different (e.g., more or less) acts than those that are described, and / or that may involve performing some acts simultaneously, even though the acts are shown as being performed sequentially in the embodiments specifically described above. Use of ordinal terms such as “first,” “second,” “third,” etc., in the claims to modify a claim element does not by itself connote any priority, precedence, or order of one claim element over another or the temporal order in which acts of a method are performed, but are used merely as labels to distinguish one claim element having a certain name from another element having a same name (but for use of the ordinal term) to distinguish the claim elements. In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

Claims

CLAIMS What is claimed is:

1. An article for delivering a therapeutic agent to a location internal to a subject, comprising: a reservoir configured to receive a therapeutic agent; a magnetic component; and a tether operably linking the reservoir and the magnetic component, wherein the article is sized and adapted for ingestion by the subject.

2. An article for administration to a subject, comprising: a reservoir defining an interior volume; a magnetic component; and a tether operably linking the reservoir and the magnetic component, wherein the article is sized and adapted for ingestion by the subject.

3. The article as in claim 2, wherein the reservoir does not include an outlet.

4. An article as in any preceding claim, wherein the reservoir is a first reservoir and the tether is a first tether, the article further comprising at least a second reservoir and at least a second tether operably linking the second reservoir to the magnetic component.

5. An article as in any preceding claim, further comprising a degradable linker operably linking the tether to the reservoir.

6. An article as in any preceding claim, wherein, in the presence of a second article comprising a second magnetic component, the article and the second article become operably linked via the magnetic component and the second magnetic component.

7. An article as in any preceding claim, further comprising a resistor associated with the magnetic component.

8. An article as in any preceding claim, wherein the second article further comprises a second reservoir operably linked to the second magnetic component by a second tether.

9. An article as in any preceding claim, wherein the reservoir comprises at least one micro-outlet having a maximum cross-sectional dimension of less than or equal to 1 millimeter.

10. An article as in any preceding claim, wherein the reservoir is configured to release a therapeutic agent at a rate of greater than or equal to 0.0001 g / day and less than or equal to 2 g / day through the at least one micro-outlet.

11. An article as in any preceding claim, wherein the tether comprises a suture, a metal, an inorganic material, and / or a polymer.

12. An article as in any preceding claim, wherein the tether is degradable.

13. An article as in any preceding claim, wherein the article comprises a first configuration within a container and, after being ingested by a subject, the article is configured to be released from the container to comprise a second configuration at a location internal to the subject.

14. A self-assembling drug delivery system, comprising: two or more articles as in any one of the preceding claims; wherein each magnetic component of each article is configured to self-assemble at the location internal to the subject such that the system resides at a location internal to the subject..

15. A system as in claim 14, wherein the two or more articles are configured to be administered to the subject substantially simultaneously.

16. A system as in claim 14, wherein the system, when assembled, is sized and adapted to prevent passage of the system through a pylorus of the subject.

17. A system as in any preceding claim, wherein the system is configured to be retained at the location internal to the subject for greater than or equal to 1 hour and less than or equal to 365 days.

18. A system as in any preceding claim, further comprising greater than or equal to 1 grams of the therapeutic agent contained within the reservoirs of the system.

19. A system as in any preceding claim, further comprising less than or equal to 100 grams of the therapeutic agent contained within the reservoirs of the system.

20. A system as in any preceding claim, further comprising greater than or equal to 0.01 grams of the therapeutic agent contained within each reservoir of the system.

21. A system as in any preceding claim, further comprising less than or equal to 10 grams of the therapeutic agent contained within each reservoir of the system.

22. A system as in any preceding claim, wherein the therapeutic agent is a first therapeutic agent and wherein the system further comprises at least a second therapeutic agent.

23. An article as in any preceding claim, wherein the reservoir comprises an actuation mechanism.

24. An article as in claim 23, wherein the actuation mechanism comprises a spring, an osmotic agent, and / or a swelling agent .

25. An article as in claim 23 or 24, wherein the actuation mechanism is configured to disassemble the system.

26. An article as in claim 23 or 24, wherein the actuation mechanism is configured to modulate a release rate of a therapeutic agent from the reservoir.

27. An article as in any preceding claim, wherein the therapeutic agent is a biological macromolecule, a small molecule, a vitamin, or a supplement.

28. The article or system as in any preceding claim, wherein the therapeutic agent is a selective serotonin reuptake inhibitor, a blood thinning agent, a steroid, an antagonist, a cardiacalycoside, an alpha blocker, a cholesterol absorption inhibitor, a metabolite, an antihistamine, an opioid, a proton-pump inhibitor, an antibiotic, an anti-malarial agent, sulfonamides, a contraceptive, a stimulant, an analgesic, an anti-analgesic, an anti- inflammatory drug, nonsteroidal anti-inflammatory drug, an antipyretic, an immunosuppressant, a neuroprotective agent, an antipsychotic, a statin, an antidepressant, an antiepileptic, an anti-proliferative, an anti-cancer agent, an antimigraine drug, an antimicrobial, an antifungal, an antiviral agent, an antiretroviral agent, an aolytic, a bacteriostatic, a sedative, a hypnotic, a bronchodilator, an anti-asthma drug, a cardiovascular drug, anesthetic, an anticoagulant, a dopaminergic, an electrolyte, a gastro-intestinal drug, a muscle relaxant, a parasympathomimetic, an anorectic, an anti- narcoleptic, a protein, a peptide, a hormone, a nucleic acid, a gene construct, 3-hy-droxy- 3-methyl-glutaryl (HMG) co-A reductase inhibitor, a mineral, 4 prostaglandin, a nutritional supplement, a corticosteroid, a nutraceutical, a plant extract, or a phytohormone.

29. The article or system as in any preceding claim, wherein the therapeutic agent is a selective serotonin reuptake inhibitor, an antidepressant, an anxiolytic, a sedative, a hypnotic, an opioid, an antimigraine drug, a cholesterol absorption inhibitor, a substance abuse treatment, an immunosuppressant, an HMG co-A reductase inhibitor, a blood thinning agent, a cardiac glycoside, an antibiotic, a contraceptive, an analgesic, an anesthetic, a nonsteroidal anti-inflammatory drug, an antiepileptic, or an alpha blocker.

30. A method of administering a therapeutic agent to a subject, comprising: administering at least two articles to the subject such that the at least two articles assemble at a location internal to the subject to form a drug delivery system, wherein each of the at least two articles comprises: a reservoir configured to receive a therapeutic agent; a magnetic component; anda tether operably linking the reservoir and the magnetic component.

31. A method as in claim 30, wherein the administering at least two articles occurs substantially simultaneously, 32. A method as in claim 30 or 31, further comprising retaining the system at the location internal to the subject for greater than or equal to 1 hour and less than or equal to 365 days.

33. A method as in any preceding claim, further comprising measuring an impedance of the magnetic components of the system.

34. A method as in any preceding claim, further comprising disassembling the system at the location internal to the subject by actuating an actuation mechanism of at least one of the articles of the system.

35. A method as in any preceding claim, further comprising administering an article comprising an actuation mechanism such that the system disassembles at the location internal to the subject.

36. A method as in any preceding claim, further comprising degrading the tether associated with the reservoir and the magnetic component of at least one of the articles to release the system from the location internal to the subject.

37. A kit, comprising: at least two articles for delivering a therapeutic agent to a location internal to a subject, wherein each of the articles comprises: a reservoir; a magnetic component; and a tether operably linking the reservoir and the magnetic component, wherein each of the articles is sized and adapted for ingestion such that the article resides at the location internal to the subject.

38. An article for gastric sensing at a location internal to a subject, comprising: a capsule defining an interior volume; a power source and / or an electronic component at least partially disposed within the interior volume of the capsule; a magnetic component; and a tether operably linking the capsule and the magnetic component, wherein the article is sized and adapted for ingestion such that the article resides at the location internal to the subject.

39. An article as in claim 38, wherein the article comprises the power source.

40. An article as in claim 38 or 39, wherein the power source is a battery.

41. An article as in any one of claims 38-40, wherein the article comprises the electronic component.

42. An article as in claim 41, wherein the electronic component comprises a sensor.

43. An article as in any one of claims 28-42, wherein the tether is a first tether, further comprising: a reservoir configured to receive a therapeutic agent; and a second tether operably linking the reservoir and the magnetic component.

44. An article as in claim 43, where the reservoir comprising the therapeutic agent.

45. A gastric sensing system, comprising two or more articles as in any one of claims 38-43.

46. A gastric sensing system, comprising: two or more capsules; at least one capsule comprising one or more electronic components; at least one capsule comprising a power source in electronic communication with the one or more electronic components;a magnetic component; and a tether operably linking the magnetic component to at least one of the two or more capsules; wherein the system is configured for extended residence at a location internal to a subject.

47. The gastric sensing system of claim 46, wherein the one or more electronic components comprises a sensor 48. A gastric sensing system as in claim 46 or 47, wherein the two or more capsules are in electronic and / or wireless communication.

49. A gastric sensing system as in claim 47, wherein the sensors comprises an alcohol sensor, a pH sensor, an accelerometer, a temperature sensor, and / or a microphone.

50. A gastric sensing system as in any one of claims 46-49, wherein at least one of the two or more capsules comprises a wireless communication component.

51. A gastric sensing system as in any one of claims 46-50, wherein the system further comprises a pulsatile drug release mechanism.

52. A gastric sensing system as in any one of claims 46-51, wherein a first capsule serves as a master device and at least a second capsule serves as a slave device.

53. A gastric sensing system as in any one of claims 46-52, further comprising a triggerable drug release reservoir in electronic and / or wireless communication with the at least one capsule.

54. A kit, comprising: at least two articles for gastric sensing, wherein each of the articles comprises: a capsule comprising an electronic component and / or a power source; a magnetic component; anda tether operably linking the reservoir and the magnetic component, wherein each of the articles is sized and adapted for ingestion such that the article resides at a location internal to a subject.

55. A kit, comprising: a first article for delivering a therapeutic agent to a location internal to a subject, comprising: a reservoir; a magnetic component; and a first tether operably linking the reservoir and the magnetic component; and a second article for gastric sensing, comprising: a capsule comprising an electronic component and / or a power source; a magnetic component; and a second tether operably linking the reservoir and the magnetic component, wherein each of the articles is sized and adapted for ingestion such that the article resides at a location internal to a subject.

Images